Mutant of RSV f protein
By introducing specific amino acid mutations in the head and tail domains of RSV F proteins, preventing conformational transformation, the problem of instability of conformational trimer state before fusion of RSV F proteins is solved, and the induction and immunity of high titer neutralizing antibodies are achieved. The improvement of prototyping provides an effective strategy for the development of RSV vaccines.
Patent Information
- Application Number
- PCT/CN2024/089988
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-04
- Filing Date
- 2024-04-26
- Publication Date
- 2024-11-07
AI Technical Summary
The prior art cannot effectively stabilize the conformational trimer state of the RSV F protein before fusion, resulting in insufficient titers of neutralizing antibodies and making it difficult to develop RSV vaccines that meet clinical needs.
The stability of the mutant was verified by performing specific amino acid mutations on the head and tail domains of the RSV F protein, preventing conformational transformation, combining AM14 monoclonal antibody experiments, and introducing additional mutations in the tail domain to enhance stability.
The RSV F protein was successfully stabilized in the conformational trimer state before fusion, which increased the neutralizing antibody titer, enhanced immunogenicity, and significantly improved the development potential of the vaccine.
Smart Images

Figure PCTCN2024089988-FTAPPB-I100001 
Figure PCTCN2024089988-FTAPPB-I100002 
Figure PCTCN2024089988-FTAPPB-I100003
Abstract
Description
RSV F protein mutants
[0001] Cross-reference instructions
[0002] This application claims priority to the Chinese patent application filed with the China Patent Office on May 4, 2023, with application number 202310489328.3 and invention name “Mutants of RSV F protein”, the entire contents of which are incorporated by reference into this application. Technical Field
[0003] The present disclosure relates to the field of biopharmaceuticals, and in particular to products such as mutants of RSV F protein, methods for stabilizing RSV F protein pre-fusion conformation trimers, and vaccines. Background Art
[0004] Respiratory syncytial virus (RSV) is a common virus that causes lung and respiratory tract infections. It causes over 30 million cases of lower respiratory tract infections worldwide each year, with approximately 3 million requiring hospitalization. RSV is particularly harmful to infants, young children, and the elderly, causing severe infections. It is the second leading cause of death in infants and young children and the leading cause of respiratory morbidity and mortality in the elderly. Currently, there is no vaccine available to prevent RSV infection.
[0005] RSV is an enveloped negative-sense single-stranded RNA virus belonging to the genus Orthopneumovirus of the family Pneumoviridae. Its genome encodes 11 proteins, including 9 structural proteins and 2 non-structural proteins. The two transmembrane glycoproteins on the surface of the virus particles, namely the attachment protein G and the fusion protein F, play an important role in the initial stage of viral infection and are the main targets of neutralizing antibodies. RSV has two subtypes, namely subtype A and subtype B. Between the two subtypes, the G protein is quite different, while the F protein is more conserved, with a sequence homology of more than 90% (Ref: Harshbarger W, et al. PLoS Pathog., 2020, 16: e1008943.).
[0006] The RSV F protein is a type I viral fusion protein responsible for membrane fusion between the virus and the host cell. In vivo, the F protein is first translated into a single-chain, inactive precursor protein, F0, consisting of 574 amino acids. The signal peptide, consisting of amino acids 1 to 25 at the N-terminus of the F0 protein, is removed by signal peptidase. Furthermore, two furin cleavage sites exist at amino acids 109 / 110 and 136 / 137 of F0. These sites are enzymatically cleaved by proteases to remove the peptide from amino acids 110 to 136 (termed p27), generating F1, consisting of amino acids 137 to 574, and F2, consisting of amino acids 26 to 109. F1 and F2 are linked by two disulfide bonds, forming the F protein monomer. In their native state, three F protein monomers further assemble into a homotrimer, which exerts its biological activity.
[0007] The RSV F protein exists in two conformational states: a prefusion conformation and a postfusion conformation. The spatial structures of these two conformations have been resolved (Ref: McLellan JS, et al. Science, 2013, 340: 1113-1117. McLellan JS, et al. J. Virol., 2011, 85: 7788-7796.). The prefusion conformation trimer is lollipop-shaped and can be visually divided into a head domain away from the viral envelope and a tail domain near the envelope. During viral infection of host cells, the refolding region 1 (RR1) of the F protein head region and the refolding region 2 (RR2) near the envelope undergo significant conformational changes. RR1 transforms from a helix, random coil and β-sheet structure to a long helix structure and extends above the head domain. RR2 flips from the proximal end of the envelope to above the head domain at the distal end of the envelope and combines with RR1 to form a six-bundle helix structure. At this time, the F protein trimer transforms from a lollipop-shaped pre-fusion conformation to a cone-shaped post-fusion conformation, leading to the occurrence of the virus and host cell membrane fusion process (Ref: Krarup A., et al. Nat. Commun., 2015, 6: 8143).
[0008] Because the F protein plays an important role in the early stages of RSV infection and is the main target of neutralizing antibodies in the human body, the F protein is one of the main target antigens for vaccine development. However, most of the highly active neutralizing antibodies produced after human infection target the prefusion conformation (Ref: Battles MB, McLellan JSNat. Rev. Microbiol., 2019, 17: 233-245). Several studies have successfully isolated and obtained high-affinity neutralizing antibodies that specifically bind to the prefusion conformation of the F protein, such as the AM14 monoclonal antibody that targets the interface between different monomers of the prefusion conformation trimer (Ref: Gilman MSA et al. PLoS Pathog., 2015, 11: e1005035.). However, the prefusion conformation of the F protein is an unstable state and can easily spontaneously transform into a postfusion conformation. Animal immunization experiments have shown that the neutralizing antibody titer induced by the F protein in the prefusion conformation is much higher than that in the postfusion conformation (Ref: Battles MB, McLellan JSNat. Rev. Microbiol., 2019, 17: 233-245; Krarup A. et al. Nat. Commun., 2015, 6: 8143). Therefore, stabilizing the RSV F protein in the prefusion conformational trimer state and preventing it from transforming to the postfusion conformation can be used as a preferred antigen for vaccine development, providing an effective strategy for the development of RSV vaccines.
[0009] However, to date, the development of vaccines targeting the RSV F protein prefusion conformation trimer has not yet met widespread clinical needs. Therefore, finding a new RSV F protein mutant that stabilizes the RSV F protein in the prefusion conformation trimer state and can induce excellent neutralizing antibody titers has become an urgent problem to be solved.
[0010] Summary of the Invention
[0011] Technical issues solved:
[0012] One aspect disclosed in the present invention is to address the lack of new RSV F protein mutants in the prior art that can stably maintain the prefusion conformational trimer state and induce the production of excellent neutralizing antibody titers. A new RSV F protein mutant and a new strategy for stabilizing the RSV F protein prefusion conformational trimer are provided.
[0013] Specifically, in the disclosed embodiment, by comparing the structure of the RSV F protein before and after fusion, other conformational change regions coupled with the RR1 conformational transition are identified in the head domain of the RSV F protein, and then sudden changes are introduced in these regions to stabilize its conformation, and the conformational transition of RR1 is prevented by coupling regulatory effects, and / or sudden changes are introduced directly in the interaction region to which RR1 is involved to prevent its conformational transition. Based on this strategy, a variety of mutation schemes are provided in the disclosed embodiment to stabilize the RSV F protein in the pre-fusion conformational trimer state. Simultaneously, in the disclosed embodiment, sudden changes are also introduced in the tail domain to further enhance the stability of the RSV F protein pre-fusion conformational trimer, thereby solving the above problems.
[0014] The technical solutions provided by this disclosure are:
[0015] A mutant of a wild-type RSV F protein, wherein the mutant has at least one amino acid mutation site compared to the wild-type RSV F protein before artificial mutation, and the amino acid mutation site includes:
[0016] (a) any position between amino acids 73 to 96; or
[0017] (b) any position between amino acids 216 to 240; or
[0018] (c) amino acid at position 141, amino acid at position 190, amino acid at position 193, amino acid at position 195, amino acid at position 199, or amino acid at position 373.
[0019] In the embodiments disclosed herein, based on the spatial structural comparison analysis of the RSV F protein before and after fusion, mutations are introduced into the head domain to prevent the conformational transition of RR1 and stabilize the F protein in the pre-fusion conformational trimer state. Binding experiments with the pre-fusion conformational trimer-specific monoclonal antibody AM14 showed that the mutants provided in the embodiments disclosed herein have a certain binding activity with the AM14 monoclonal antibody, while the wild-type RSV F protein before artificial mutation has no binding activity with the AM14 monoclonal antibody. Binding experiments showed that the mutants provided in the embodiments of the present disclosure and the wild-type RSV F protein before artificial mutation all had strong binding activity with palivizumab. The above experimental results show that the introduced mutations successfully stabilized the RSV F protein in a pre-fusion conformational trimer state and folded well. Therefore, any combination of the technical solutions provided in the above embodiments of the present disclosure can solve the problems in the prior art and achieve the same or similar technical effects.
[0020] In an embodiment of the present disclosure, the above-mentioned amino acids 73 to 96 and amino acids 216 to 240 are located in the α1 helix and α5 helix (as shown in FIG2 ) of the head domain (as shown in FIG1A ) of the trimer in the pre-fusion conformation of the wild-type RSV F protein. The head domain is defined in the present invention for the purpose of vividly describing the structure of the RSV F protein. We define amino acids 1 to 485 as the head domain, and amino acids 486 to the C-terminus of the F protein as the tail domain. The approximate spatial positions of the head domain and the tail domain are shown in FIG1A . In an embodiment of the present disclosure, the above-mentioned α1 helix or α5 helix refers to the first or fifth α helix starting from the N-terminus in the head domain, which is approximately located at amino acids 73 to 96 and amino acids 216 to 240 in the primary structure of the RSV F protein. Based on the research results disclosed herein, it is believed that mutation of any amino acid in the α1 helix or α5 helix of the head domain of the RSV F protein prefusion conformation trimer will stabilize the RSV F protein in the prefusion conformation trimer state. Therefore, the amino acids 73 to 96 and 216 to 240 described in this disclosure may have one or more, for example, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid position shifts, which are also considered to be included in the scope of protection of this disclosure.
[0021] In the embodiments of the present disclosure, the amino acid positions are numbered based on the wild-type RSV F protein as a reference, starting with the first amino acid in its amino acid sequence. For example, the 73rd amino acid is counted starting from the first amino acid methionine in the wild-type RSV F protein sequence MELPILKA.
[0022] In embodiments of the present disclosure, the artificial mutations generally refer to substitutions, deletions, or insertions of amino acid residues in the wild-type RSV F protein. However, in some embodiments, the artificial mutations only refer to substitutions of amino acid residues. The mutants described in the present disclosure are obtained by such artificial mutations.
[0023] In some other embodiments, the mutant has multiple amino acid mutation sites compared to the wild-type RSV F protein before artificial mutation, and the multiple amino acid mutation sites may include:
[0024] (a) at least two positions selected from any of amino acids 73 to 96; or
[0025] (b) at least two positions selected from any of amino acids 216 to 240; or
[0026] (c) at least one arbitrary position selected from amino acids 73 to 96, and at least one arbitrary position selected from amino acids 216 to 240.
[0027] Furthermore, in some other embodiments, the mutant has multiple amino acid mutation sites compared to the wild-type RSV F protein before artificial mutation, and the multiple amino acid mutation sites may include any one of the following (a), (b) or (c) and a combination of (d):
[0028] (a) at least two positions selected from any of amino acids 73 to 96;
[0029] (b) at least two positions selected from any of amino acids 216 to 240;
[0030] (c) at least one selected from any position among amino acids 73 to 96, and at least one selected from any position among amino acids 216 to 240;
[0031] (d) at least one site selected from L141, S190, L193, L195, I199 or L373.
[0032] In some embodiments, the plurality can be, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more.
[0033] In some embodiments, the above-mentioned amino acid mutation site can be: at least one selected from amino acid position 79, amino acid position 82, amino acid position 92, amino acid position 93, amino acid position 96, amino acid position 141, amino acid position 190, amino acid position 193, amino acid position 195, amino acid position 199, amino acid position 220, amino acid position 224, amino acid position 227, amino acid position 230, amino acid position 234, amino acid position 238 or amino acid position 373.
[0034] Furthermore, in some other embodiments, the amino acid mutation sites may include the following:
[0035] (1) amino acid at position 92; or
[0036] (2) amino acid at position 96; or
[0037] (3) amino acid 227; or
[0038] (4) amino acid 230; or
[0039] (5) amino acid 238; or
[0040] (6) amino acid 227 and amino acid 230; or
[0041] (7) amino acid at position 82 and amino acid at position 227; or
[0042] (8) amino acid 89 and amino acid 227; or
[0043] (9) amino acid at position 92 and amino acid at position 227; or
[0044] (10) amino acid at position 92 and amino acid at position 230; or
[0045] (11) amino acid at position 96 and amino acid at position 227; or
[0046] (12) amino acid at position 96 and amino acid at position 230; or
[0047] (13) amino acid at position 96 and amino acid at position 238; or
[0048] (14) amino acid 93 and amino acid 227; or
[0049] (15) amino acid at position 89 and amino acid at position 230; or
[0050] (16) amino acid at position 82 and amino acid at position 230; or
[0051] (17) amino acid at position 93 and amino acid at position 230; or
[0052] (18) amino acid 227 and amino acid 238; or
[0053] (19) amino acid 230 and amino acid 238; or
[0054] (20) amino acid 227 and amino acid 234; or
[0055] (21) amino acid at position 82 and amino acid at position 234; or
[0056] (22) amino acid 193 and amino acid 195; or
[0057] (23) amino acid 190, amino acid 193, and amino acid 195; or
[0058] (24) amino acid 193 and amino acid 199; or
[0059] (25) amino acid 141 and amino acid 373; or
[0060] (26) amino acid at position 82 and amino acid at position 224; or
[0061] (27) amino acid at position 92 and amino acid at position 238; or
[0062] (28) amino acid 79 and amino acid 220; or
[0063] (29) amino acid 97 and amino acid 291; or
[0064] (30) amino acid at position 93 and amino acid at position 234; or
[0065] (31) amino acid at position 92 and amino acid at position 234; or
[0066] (32) amino acid 193, amino acid 227, and amino acid 230; or
[0067] (33) amino acid 190, amino acid 193, and amino acid 230; or
[0068] (34) amino acid 193 and amino acid 230; or
[0069] (35) amino acid 190, amino acid 193, amino acid 227, and amino acid 230; or
[0070] (36) amino acid at position 93, amino acid at position 230, and amino acid at position 234; or
[0071] (37) amino acid at position 93, amino acid at position 193, amino acid at position 230, and amino acid at position 234; or
[0072] (38) amino acid 93, amino acid 190, amino acid 193, and amino acid 234; or
[0073] (39) amino acid at position 93, amino acid at position 227, amino acid at position 193, and amino acid at position 234; or
[0074] (40) amino acid 93, amino acid 234, and amino acid 373; or
[0075] (41) amino acid 230, amino acid 238, and amino acid 373; or
[0076] (42) amino acid 93, amino acid 141, and amino acid 234; or
[0077] (43) amino acid 93, amino acid 141, amino acid 230, and amino acid 234; or
[0078] (44) amino acid 141, amino acid 230, and amino acid 238; or
[0079] (45) amino acid 227, amino acid 230, and amino acid 373; or
[0080] (46) amino acid 93, amino acid 227, and amino acid 234; or
[0081] (47) amino acid 93, amino acid 227, amino acid 230, and amino acid 234; or
[0082] (48) amino acid at position 93, amino acid at position 227, amino acid at position 234, and amino acid at position 373; or
[0083] (49) amino acid 227, amino acid 230, amino acid 238, and amino acid 373.
[0084] Furthermore, in some embodiments, the amino acid mutation sites may include the following:
[0085] (1) amino acid at position 92; or
[0086] (2) amino acid at position 96; or
[0087] (3) amino acid 227; or
[0088] (4) amino acid 230; or
[0089] (5) amino acid 238; or
[0090] (6) amino acid 227 and amino acid 230; or
[0091] (7) amino acid at position 92 and amino acid at position 227; or
[0092] (8) amino acid at position 92 and amino acid at position 230; or
[0093] (9) amino acid 227 and amino acid 238; or
[0094] (10) amino acid 230 and amino acid 238; or
[0095] (11) amino acid at position 93 and amino acid at position 234; or
[0096] (12) amino acid at position 92 and amino acid at position 234; or
[0097] (13) amino acid 193, amino acid 227, and amino acid 230; or
[0098] (14) amino acid 190, amino acid 193, amino acid 227, and amino acid 230; or
[0099] (15) amino acid at position 93, amino acid at position 230, and amino acid at position 234; or
[0100] (16) amino acid at position 93, amino acid at position 234, and amino acid at position 373; or
[0101] (17) amino acid 230, amino acid 238, and amino acid 373; or
[0102] (18) amino acid 93, amino acid 141, and amino acid 234; or
[0103] (19) amino acid at position 93, amino acid at position 141, amino acid at position 230, and amino acid at position 234; or
[0104] (20) amino acid 141, amino acid 230, and amino acid 238; or
[0105] (21) amino acid 227, amino acid 230, and amino acid 373; or
[0106] (22) amino acid 93, amino acid 227, and amino acid 234; or
[0107] (23) amino acid position 93, amino acid position 227, amino acid position 234, and amino acid position 373; or
[0108] (24) amino acid 190, amino acid 193, and amino acid 230; or
[0109] (25) amino acid 193 and amino acid 230; or
[0110] (26) amino acid at position 93, amino acid at position 193, amino acid at position 230, and amino acid at position 234; or
[0111] (27) amino acid at position 93, amino acid at position 190, amino acid at position 193, and amino acid at position 234; or
[0112] (28) amino acid at position 93, amino acid at position 227, amino acid at position 193, and amino acid at position 234; or
[0113] (29) amino acid 93, amino acid 227, amino acid 230, and amino acid 234; or
[0114] (30) amino acid 227, amino acid 230, amino acid 238, and amino acid 373.
[0115] In order to further improve the stability of the RSV F protein pre-fusion conformation trimer, in some embodiments, the amino acid mutation site further includes: at least one site selected from any of amino acids 486 to 513.
[0116] Binding experiments with the pre-fusion conformation trimer-specific monoclonal antibody AM14 showed that the mutants provided in the embodiments of the present disclosure have strong binding activity with the AM14 monoclonal antibody, while the wild-type RSV F protein before artificial mutation has no binding activity with the AM14 monoclonal antibody. Binding experiments show that the mutants provided in the embodiments of the present disclosure and the wild-type RSV F protein before artificial mutation have strong binding activity with palivizumab. The above experimental results show that the introduced mutations successfully stabilized the RSV F protein in a pre-fusion conformational trimer state and folded well. In the embodiments of the present disclosure, an accelerated stability test was also carried out on the above-expressed F protein mutants. The results showed that after being placed in a 37°C environment for 4 weeks, there was no obvious change in the binding activity of AM14 monoclonal antibody, indicating that the mutant protein pre-fusion conformational trimer remained stable. Animal immunization experiments were also carried out in the embodiments of the present disclosure, and the experimental results showed that compared with the wild-type RSV F protein before artificial mutation, the mutants provided in the embodiments of the present disclosure can induce the production of higher titers of neutralizing antibodies. Therefore, any combination of the technical solutions provided in the above-mentioned embodiments of the present disclosure can solve the problems in the prior art and achieve the same or similar technical effects.
[0117] In the embodiment of the present disclosure, the above-mentioned 486th to 513th amino acid is positioned at the tail domain (as shown in Figure 1A) of the wild-type RSV F protein pre-fusion conformation trimer. The tail domain is defined by the present invention in order to vividly describe the structure of RSV F protein. We define the 1st to 485th amino acid as the head domain, and the 486th amino acid to the C-terminal of the F protein as the tail domain. The approximate spatial position of the head domain and the tail domain is as shown in Figure 1A. Based on the research results disclosed herein, it can be believed that the mutation of any amino acid in the 486th to 513th amino acid of the tail domain of the RSV F protein pre-fusion conformation trimer will further stabilize the RSV F protein pre-fusion conformation trimer structure. Therefore, the 486th to 513th amino acid described in the present disclosure can have one or more, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10 amino acid positions are offset, which is also considered to be included within the scope of protection disclosed herein.
[0118] Therefore, in some embodiments, the above-mentioned amino acid mutation site further includes: at least one selected from the group consisting of amino acid at position 501, amino acid at position 502, amino acid at position 505, amino acid at position 509, and amino acid at position 512.
[0119] Furthermore, in some other embodiments, the amino acid mutation site may also include the following:
[0120] (1) amino acid 509; or
[0121] (2) amino acid at position 505; or
[0122] (3) amino acid at position 502; or
[0123] (4) amino acid 501; or
[0124] (5) amino acid 505 and amino acid 509; or
[0125] (6) amino acid at position 502 and amino acid at position 509; or
[0126] (7) amino acid 501 and amino acid 509; or
[0127] (8) amino acid at position 502 and amino acid at position 505; or
[0128] (9) amino acid 501 and amino acid 505; or
[0129] (10) amino acid at position 502, amino acid at position 505, and amino acid at position 509; or
[0130] (11) Amino acid at position 501, amino acid at position 505 and amino acid at position 509.
[0131] Furthermore, in some embodiments, the amino acid mutation site also includes the following situations:
[0132] (1) amino acid 509; or
[0133] (2) amino acid at position 505; or
[0134] (3) amino acid at position 505 and amino acid at position 509; or
[0135] (4) amino acid at position 502 and amino acid at position 509; or
[0136] (5) Amino acid at position 501 and amino acid at position S509.
[0137] RSV F protein has two subtypes, A and B, and there is a very high sequence conservation between the two subtypes, with its amino acid sequence homology reaching 90%. The amino acid sequence homology between different strains within subtype A and subtype B is higher. And the RSV F protein of various subtypes and strains thereof is composed of 574 amino acids. In view of the high conservation of amino acid sequences between different subtypes of RSV F protein, the mutation scheme provided in the present disclosure is applicable to any strain sequence of RSV F protein subtype A and subtype B or strain sequence that may appear in the future. In the embodiment of the present disclosure, the wild-type RSV F protein sequence can be from any known or future F protein sequence that may appear, including but not limited to the F protein sequence from any RSV strain of subtype A or subtype B, such as the F protein sequence of the A2 strain of subtype A shown in SEQ ID NO.1-2, the F protein sequence of the ON1 strain of subtype A shown in SEQ ID NO.3, and the F protein sequence of the subtype B strain shown in SEQ ID NO.4-6. Because the sequence of the wild-type RSV F protein is highly conserved or identical across RSV subtypes and strains, minor differences in the wild-type RSV F protein sequence are tolerated, and these minor differences may be substitutions, deletions, or insertions of amino acid residues. Therefore, in some embodiments, the sequences of the wild-type RSV F proteins may be more than 90% identical, for example, more than 91%, more than 92%, more than 93%, more than 94%, more than 95%, more than 96%, more than 97%, more than 98%, or more than 99%, and have the same or substantially the same biological function.
[0138] Based on the research results disclosed herein, in some embodiments, the wild-type RSV F protein can be in the following form:
[0139] (a) an F0 precursor protein comprising two protease cleavage sites; or
[0140] (b) an F0 precursor protein that is incapable of binding a protease; or
[0141] (c) a combination of an independent F1 polypeptide and an independent F2 polypeptide; or
[0142] (d) a combination of F2 polypeptide-linker-F1 polypeptide; or
[0143] (e) An F2' polypeptide-linker-F1' polypeptide combination, wherein the F2' polypeptide has 1 to 10 fewer amino acid residues than the F2 polypeptide along the N-terminal direction, and the F1' polypeptide has 1 to 10 fewer amino acid residues than the F1 polypeptide along the C-terminal direction.
[0144] In some embodiments, the wild-type RSV F protein can be an original F0 precursor protein, i.e., comprising F1 polypeptide, F2 polypeptide, P27 peptide, optionally comprising a protein of a transmembrane domain and an intracellular domain. The F0 precursor protein contains an enzyme cleavage site for a protease, such as furin, trypsin, factor Xa, thrombin, or cathepsin L, etc. Generally, the protease is furin. During expression, it is naturally cleaved by the protease in the expression system, thereby losing the P27 peptide, and the F1 polypeptide and the F2 polypeptide jointly form the mature form of the F protein. In other embodiments, the wild-type RSV F protein can be an F0 precursor protein that cannot bind to a protease, i.e., comprising F1 polypeptide, F2 polypeptide, P27 peptide, optionally comprising a protein of a transmembrane domain and an intracellular domain, but cannot bind to a protease, thereby retaining the P27 peptide. The protease can be, for example, furin, trypsin, factor Xa, thrombin, or cathepsin L, etc. Generally, the protease is furin. In some embodiments, the wild-type RSV F protein can be a combination of an independent F1 polypeptide and an independent F2 polypeptide, optionally comprising a protein of a transmembrane domain and an intracellular domain. The F1 polypeptide and the F2 polypeptide spontaneously form an F2-F1 polypeptide heterodimer. During in vitro expression, the F1 polypeptide and the F2 polypeptide need to be expressed respectively. In some embodiments, the wild-type RSV F protein can be a combination of an F2 polypeptide-connector-F1 polypeptide, namely comprising an F1 polypeptide, an F2 polypeptide and a connector (Linker-1), optionally comprising a protein of a transmembrane domain and an intracellular domain. In other embodiments, the wild-type RSV F protein can be a combination of an F2' peptide-linker-F1' peptide, wherein the F2' peptide has 1-10 fewer amino acid residues than the F2 peptide along the N-terminal direction, and the F1' peptide has 1-10 fewer amino acid residues than the F1 peptide along the C-terminal direction. This means that the longer sequence in the F0 sequence, including the P27 peptide, is replaced with a linker. Studies have shown that replacing the P27 peptide with a shorter linker can increase protein expression and trimer content (Ref: Krarup A. et al. Nat. Commun., 2015, 6:8143). Therefore, in one embodiment, the sequence at positions 107-138 (RARRELPRFMNYTLNNAKKTNVTLSKKRKRRF), which contains the P27 peptide and the furin cleavage site, is replaced with the QARGSGSGRS sequence.
[0145] In some embodiments, the wild-type RSV F protein before artificial mutation may comprise a sequence as shown in SEQ ID No. 7-34 in the sequence listing, or a sequence having more than 90% identity thereto, for example, more than 91%, more than 92%, more than 93%, more than 94%, more than 95%, more than 96%, more than 97%, more than 98%, more than 99%, and having the same or substantially the same biological function.
[0146] Based on the research results disclosed herein, in some embodiments, a combination of amino acid residues after the amino acid mutation site is substituted is also provided. The amino acid mutation site includes at least one of the following:
[0147] (1) amino acid 79 is substituted by C and amino acid 220 is substituted by C; or
[0148] (2) amino acid 82 is substituted by C and amino acid 224 is substituted by C; or
[0149] (3) amino acid 92 is substituted by C and amino acid 234 is substituted by C; or
[0150] (4) amino acid 93 is substituted by C and amino acid 234 is substituted by C; or
[0151] (5) amino acid at position 82 is substituted by L; or
[0152] (6) the amino acid at position 92 is substituted by L, I, M, F, Y, or W; or
[0153] (7) amino acid at position 96 is substituted by M or Y; or
[0154] (8) amino acid 141 is substituted by M, F, Y or W; or
[0155] (9) amino acid 190 is substituted by V; or
[0156] (10) amino acid 193 is substituted by M, F, Y or W; or
[0157] (11) amino acid 195 is substituted by M, F, Y or W; or
[0158] (12) amino acid 199 is substituted by M, F, Y or W; or
[0159] (13) amino acid 227 is substituted by A, V, L, I, M, S, T or Q; or
[0160] (14) amino acid 230 is substituted by F; or
[0161] (15) amino acid at position 238 is substituted by L, I, M, F, Y or W; or
[0162] (16) The amino acid at position 373 is substituted by M, F, or Y.
[0163] Furthermore, in some embodiments, the amino acid mutation sites include the following:
[0164] (1) the amino acid at position 92 is substituted by I, M, F, Y, or W; or
[0165] (2) amino acid at position 96 is substituted by Y; or
[0166] (3) amino acid 227 is substituted by M, V, or I; or
[0167] (4) amino acid 230 is substituted by F; or
[0168] (5) amino acid 238 is substituted by L, I, M or W; or
[0169] (6) amino acid 227 is substituted by M or V, and amino acid 230 is substituted by F; or
[0170] (7) amino acid 82 is substituted by L and amino acid 227 is substituted by M; or
[0171] (8) amino acid at position 92 is substituted by M or L, and amino acid at position 227 is substituted by M or V; or
[0172] (9) amino acid at position 92 is substituted by M or L, and amino acid at position 230 is substituted by F; or
[0173] (10) amino acid 96 is substituted by Y and amino acid 227 is substituted by M or V; or
[0174] (11) amino acid 96 is substituted by Y and amino acid 230 is substituted by F; or
[0175] (12) the amino acid at position 96 is substituted by Y, and the amino acid at position 238 is substituted by L, I, M or W; or
[0176] (13) amino acid 89 is substituted by L and amino acid 230 is substituted by F; or
[0177] (14) amino acid 227 is substituted by M and amino acid 238 is substituted by L, I, M or W; or
[0178] (15) the amino acid at position 230 is substituted by F, and the amino acid at position 238 is substituted by L, I, M or W; or
[0179] (16) amino acid 193 is substituted by M, and amino acid 195 is substituted by M, F or Y; or
[0180] (17) amino acid 190 is substituted by V, amino acid 193 is substituted by M, and amino acid 195 is substituted by M, F, or Y; or
[0181] (18) amino acid 193 is substituted by M, and amino acid 199 is substituted by M or F; or
[0182] (19) amino acid 141 is substituted by M or F, and amino acid 373 is substituted by M, F or Y; or
[0183] (20) amino acid 82 is substituted by C and amino acid 224 is substituted by C; or
[0184] (21) amino acid at position 92 is substituted by C, and amino acid at position 238 is substituted by C; or
[0185] (22) amino acid 79 is substituted by C and amino acid 220 is substituted by C; or
[0186] (23) amino acid 93 is substituted by C and amino acid 234 is substituted by C; or
[0187] (24) amino acid 92 is substituted by C and amino acid 234 is substituted by C; or
[0188] (25) amino acid 193 is substituted by M, amino acid 227 is substituted by M or V, and amino acid 230 is substituted by F; or
[0189] (26) amino acid 190 is substituted by V, amino acid 193 is substituted by M, and amino acid 230 is substituted by F; or
[0190] (27) amino acid 193 is substituted by M and amino acid 230 is substituted by F; or
[0191] (28) amino acid 190 is substituted by V, amino acid 193 is substituted by M, amino acid 227 is substituted by M or V, and amino acid 230 is substituted by F; or
[0192] (29) amino acid 93 is substituted by C, amino acid 230 is substituted by F, and amino acid 234 is substituted by C; or
[0193] (30) amino acid position 93 is substituted by C, amino acid position 193 is substituted by M, amino acid position 230 is substituted by F, and amino acid position 234 is substituted by C; or
[0194] (31) amino acid at position 93 is substituted by C, amino acid at position 190 is substituted by V, amino acid at position 193 is substituted by M, and amino acid at position 234 is substituted by C; or
[0195] (32) amino acid at position 93 is substituted by C, amino acid at position 227 is substituted by M or V, and amino acid at position 234 is substituted by C; or
[0196] (33) amino acid position 93 is substituted by C, amino acid position 193 is substituted by M, amino acid position 227 is substituted by M or V, and amino acid position 234 is substituted by C; or
[0197] (34) amino acid at position 93 is substituted by C, amino acid at position 234 is substituted by C, and amino acid at position 373 is substituted by M, F, or Y; or
[0198] (35) amino acid 230 is substituted by F, amino acid 238 is substituted by L, I, M or W, and amino acid 373 is substituted by M, F or Y; or
[0199] (36) amino acid position 93 is substituted by C, amino acid position 141 is substituted by M or F, and amino acid position 234 is substituted by C; or
[0200] (37) amino acid position 93 is substituted by C, amino acid position 141 is substituted by M or F, amino acid position 230 is substituted by F, and amino acid position 234 is substituted by C; or
[0201] (38) amino acid 141 is substituted by M or F, amino acid 230 is substituted by F, and amino acid 238 is substituted by L, I, M or W; or
[0202] (39) amino acid position 227 is substituted by M or V, amino acid position 230 is substituted by F, and amino acid position 373 is substituted by M, F or Y; or
[0203] (40) amino acid position 93 is substituted by C, amino acid position 227 is substituted by M or V, amino acid position 230 is substituted by F, and amino acid position 234 is substituted by C; or
[0204] (41) amino acid at position 93 is substituted by C, amino acid at position 227 is substituted by M or V, amino acid at position 234 is substituted by C, and amino acid at position 373 is substituted by M, F or Y; or
[0205] (42) The amino acid at position 227 is substituted by M or V, the amino acid at position 230 is substituted by F, the amino acid at position 238 is substituted by L, I, M, or W, and the amino acid at position 373 is substituted by M, F, or Y.
[0206] Furthermore, in some embodiments, the amino acid mutation sites may include the following:
[0207] (1) the amino acid at position 92 is substituted by I, M, F, Y, or W; or
[0208] (2) amino acid at position 96 is substituted by Y; or
[0209] (3) amino acid 227 is substituted by M or V; or
[0210] (4) amino acid 230 is substituted by F; or
[0211] (5) amino acid 238 is substituted by L, I, M or W; or
[0212] (6) amino acid 227 is substituted by M or V, and amino acid 230 is substituted by F; or
[0213] (7) amino acid at position 92 is substituted by M, and amino acid at position 227 is substituted by M or V; or
[0214] (8) amino acid at position 92 is substituted by M, and amino acid at position 230 is substituted by F; or
[0215] (9) amino acid 227 is substituted by M or V, and amino acid 238 is substituted by L or I; or
[0216] (10) the amino acid at position 230 is substituted by F, and the amino acid at position 238 is substituted by L or I; or
[0217] (11) amino acid 96 is substituted by Y and amino acid 227 is substituted by M or V; or
[0218] (12) amino acid 96 is substituted by Y and amino acid 230 is substituted by F; or
[0219] (13) the amino acid at position 96 is substituted by Y, and the amino acid at position 238 is substituted by L, I, M or W; or
[0220] (14) amino acid at position 93 is substituted by C, and amino acid at position 234 is substituted by C; or
[0221] (15) amino acid at position 92 is substituted by C, and amino acid at position 234 is substituted by C; or
[0222] (16) amino acid 193 is substituted by M, amino acid 227 is substituted by M or V, and amino acid 230 is substituted by F; or
[0223] (17) amino acid 190 is substituted by V, amino acid 193 is substituted by M, amino acid 227 is substituted by M or V, and amino acid 230 is substituted by F; or
[0224] (18) amino acid 93 is substituted by C, amino acid 230 is substituted by F, and amino acid 234 is substituted by C; or
[0225] (19) amino acid at position 93 is substituted by C, amino acid at position 234 is substituted by C, and amino acid at position 373 is substituted by M or F; or
[0226] (20) amino acid position 230 is substituted by F, amino acid position 238 is substituted by L or I, and amino acid position 373 is substituted by M or F; or
[0227] (21) amino acid at position 93 is substituted by C, amino acid at position 141 is substituted by M or F, and amino acid at position 234 is substituted by C; or
[0228] (22) amino acid position 93 is substituted by C, amino acid position 141 is substituted by M or F, amino acid position 230 is substituted by F, and amino acid position 234 is substituted by C; or
[0229] (23) amino acid 141 is substituted by M or F, amino acid 230 is substituted by F, and amino acid 238 is substituted by L or I; or
[0230] (24) amino acid position 227 is substituted by M or V, amino acid position 230 is substituted by F, and amino acid position 373 is substituted by M or F; or
[0231] (25) amino acid position 93 is substituted by C, amino acid position 227 is substituted by M or V, and amino acid position 234 is substituted by C; or
[0232] (26) amino acid position 93 is substituted by C, amino acid position 227 is substituted by M or V, amino acid position 234 is substituted by C, and amino acid position 373 is substituted by M or F; or
[0233] (27) amino acid 190 is substituted by V, amino acid 193 is substituted by M, and amino acid 230 is substituted by F; or
[0234] (28) amino acid 193 is substituted by M, and amino acid 230 is substituted by F; or
[0235] (29) amino acid position 93 is substituted by C, amino acid position 193 is substituted by M, amino acid position 230 is substituted by F, and amino acid position 234 is substituted by C; or
[0236] (30) amino acid 93 is substituted by C, amino acid 190 is substituted by V, amino acid 193 is substituted by M and amino acid 234 is substituted by C; or
[0237] (31) The amino acid at position 93 is substituted by C, or the amino acid at position 227 is substituted by M or V, the amino acid at position 193 is substituted by M, and the amino acid at position 234 is substituted by C.
[0238] (32) The amino acid at position 93 is substituted by C, the amino acid at position 227 is substituted by M or V, the amino acid at position 230 is substituted by F, and the amino acid at position 234 is substituted by C.
[0239] (33) The amino acid at position 227 is substituted by M or V, the amino acid at position 230 is substituted by F, the amino acid at position 238 is substituted by L or I, and the amino acid at position 373 is substituted by M or F.
[0240] In order to further improve the stability of the RSV F protein prefusion conformation trimer, in some embodiments, amino acid mutation sites are also introduced into the tail domain, and the amino acid mutation sites also include the following:
[0241] (1) the amino acid at position 501 is substituted by V, L, I, M, F, W, Y, P, or R; or
[0242] (2) the amino acid at position 502 is substituted by V, L, I, M, F, W, Y, P, or R; or
[0243] (3) amino acid at position 505 is substituted by M or W; or
[0244] (4) the amino acid at position 509 is substituted by G, A, V, L, I, M, F, W, P, S, T, C, Y, Q, K, R, or H; or
[0245] (5) The amino acid at position 512 is substituted by I, F, M, Y, R, or K.
[0246] Furthermore, in some embodiments, the amino acid mutation site also includes the following situations:
[0247] (1) amino acid 509 is substituted by F, M or L; or
[0248] (2) amino acid at position 505 is substituted by W; or
[0249] (3) amino acid at position 502 is substituted by Y; or
[0250] (4) amino acid 501 is substituted by M; or
[0251] (5) amino acid 505 is substituted by W and amino acid 509 is substituted by F, L or M; or
[0252] (6) amino acid 502 is substituted by Y and amino acid 509 is substituted by F; or
[0253] (7) amino acid 501 is substituted by M and amino acid 509 is substituted by F; or
[0254] (8) amino acid 502 is substituted by Y and amino acid 505 is substituted by W; or
[0255] (9) amino acid 501 is substituted by M and amino acid 505 is substituted by W; or
[0256] (10) amino acid position 502 is substituted by Y, amino acid position 505 is substituted by W, and amino acid position 509 is substituted by F; or
[0257] (11) The amino acid at position 501 is substituted by M, the amino acid at position 505 is substituted by W, and the amino acid at position 509 is substituted by F.
[0258] Furthermore, in some embodiments, the amino acid mutation site also includes the following situations:
[0259] (1) amino acid 509 is substituted by F, M or L; or
[0260] (2) amino acid at position 505 is substituted by W; or
[0261] (3) amino acid 505 is substituted by W, and amino acid 509 is substituted by F or L; or
[0262] (4) the amino acid at position 502 is substituted by Y, and the amino acid at position 509 is substituted by F; or
[0263] (5) The amino acid at position 501 is substituted by M, and the amino acid at position 509 is substituted by F.
[0264] In some embodiments, specific examples of the mutants may include sequences selected from the group consisting of SEQ ID No. 35-166 in the sequence listing, or sequences having 90% or more identity thereto, for example, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, and having the same or substantially the same biological function.
[0265] The C-terminus of the full-length RSV F protein contains a transmembrane region and an intracellular region. In some embodiments, the transmembrane region and / or the intracellular region can be retained or removed. To facilitate secretory expression, in some embodiments, the transmembrane region and the intracellular region at the C-terminus of the F protein are removed to obtain a soluble F protein. In other embodiments of the present disclosure, the intracellular region and all or part of the transmembrane region can be removed, or a longer sequence containing the transmembrane region and the intracellular region at the C-terminus can be removed. In some specific embodiments of the present disclosure, amino acids 514 to 574 are removed from the C-terminus.
[0266] In some embodiments, the mutant can be in a trimeric form. The native structure of the RSV F protein is a homotrimer. Therefore, preferably, in some embodiments, the trimeric form can be a homotrimer. When the transmembrane region and the intracellular region are retained or removed, the C-terminus of the F protein can be directly or indirectly connected to an exogenous trimerization domain to promote the formation of a trimeric structure. Exogenous multimerization domains are known in the art, such as GCN4 leucine zipper (Ref: Sliepen K. et al. J. Biol. Chem., 2015, 290: 7436-7442), collagen (Ref: McAlinden A. et al. J. Biol. Chem., 2003, 278: 42200-42207), T4 foldon (Ref: 1. McLellan J Set al. Science, 2013, 342: 592-598. 2. Joyce M Get al. Nat. Struct. Mol. Biol., 2016, 23: 811-820), etc. In some embodiments, the C-terminus of the F protein is linked to T4 foldon to promote its trimerization.
[0267] In some embodiments, the mutant may be modified to achieve certain functions without affecting the overall biological activity of the mutant, for example, immunogenicity. The modification may be at least one selected from glycosylation, phosphorylation, methylation, coenzyme modification, or acylation.
[0268] When the exogenous multimerization domain is connected to the F protein, it can be directly connected to the C-terminus of the F protein or connected through a linker (Linker-2). The linker can be long or short. In some embodiments, it can be, for example, a GS repeat sequence, a GGS repeat sequence, a SAIG repeat sequence, a GSS repeat sequence, or a GG repeat sequence. These linkers and other similar linkers are well known in the art and can be used in the mutants disclosed herein. In some specific examples, the F protein and the exogenous multimerization domain are connected via a SAIG linker.
[0269] To achieve certain specific purposes or functions, in some embodiments, the mutant may also include a functional tag. This tag can be added at an appropriate location. For example, the functional tag can be selected from one or more of a signal peptide, a tag, or an immunopotentiating peptide. The signal peptide may facilitate protein expression; the tag may be, for example, a Flag tag, enhanced green fluorescent protein (eGFP), glutathione sulfhydryltransferase (GST), etc., and may be used for detection, purification, separation, etc. The functional sequences described above may be used in any combination. In some embodiments, to facilitate purification of the target protein, the constructed F protein mutant may contain a His tag (composed of multiple His tags linked together), a streptomycin tag II, an AviTag tag, and may also include a TEV protease cleavage site for the removal of additional sequences. These additional sequences are well known to those skilled in the art, and their inclusion or absence does not affect the biological function of the F protein. In other embodiments, after the F protein is linked to an exogenous multimerization domain, a His tag (HHHHHHHH) is attached via a GSGSGS linker to facilitate purification of the target protein. In some other embodiments, in addition to the His tag, a streptomycin tag II, an AviTag tag, and a TEV protease cleavage site are also connected. The mutant sequences disclosed in the present disclosure do not contain these additional tag sequences.
[0270] In the present disclosure, the mutant of the wild-type RSV F protein can be prepared by conventional means in the prior art according to the content recorded in the present disclosure, for example, the nucleotide sequence encoding the mutant is loaded into a suitable vector and expressed and purified in a corresponding expression system. Li Qiming et al. disclose several new expression vectors for respiratory syncytial virus in Chinese patents with publication numbers CN111166881A, CN106986942A and CN106986943A. The expression of RSV F protein mutants can use suitable host cells in the prior art, for example, Escherichia coli, yeast cells, insect cells or mammalian cells. Examples of Escherichia coli expression systems include GI698, ER2566, BL21 (DE3), XA90, DH (5a), B834 (DE3), and BLR (DE3). Examples of yeast expression systems include Saccharomyces cerevisiae, Pichia pastoris, and Hansenula. Examples of insect cells include Sf9 cells, Sf21 cells, Tn5 cells, Schneider S2 cells, and High Five cells. Examples of mammalian cells include CHO cells, human embryonic kidney cells, NIH-3T3 cells, 293-T cells, Vero cells, and HeLa cells. The obtained protein can be purified by any suitable method, such as salting out, precipitation, dialysis or ultrafiltration, molecular sieve chromatography, ion exchange chromatography, hydrophobic chromatography, and affinity chromatography.
[0271] Another aspect of the present invention provides virus-like particles (VLPs) comprising the mutants described herein. The VLPs can be prepared using any suitable method known in the art. For example, VLPs can be expressed using specific insect or mammalian cell expression systems.
[0272] Another aspect of the present invention provides an isolated nucleic acid molecule encoding a mutant described herein. In some embodiments, the isolated nucleic acid molecule is a DNA molecule. Generally, the codons encoding the amino acids of the mutant described in the embodiments of the present invention can be optimized to optimize their expression in the host cell. In other embodiments, the isolated nucleic acid molecule is an RNA molecule, including an mRNA molecule.
[0273] Another aspect of the present invention is to provide a vector comprising the sequence of the nucleic acid molecule described in the present disclosure or the mutant described in the present disclosure. In some embodiments, the vector is a protein expression vector. In other embodiments, the vector is a gene delivery vector. For example, a viral vector or a non-viral vector. In other embodiments, the viral vector includes a retroviral vector, a lentiviral vector, an adenoviral vector, an adeno-associated viral vector, a poxvirus vector, a herpes simplex virus vector or a Sendai virus vector. The vector may contain regulatory sequences such as promoters and terminators, as well as marker sequences such as drug-resistant genes and reporter genes. In addition, the above-mentioned vector may also contain a sequence encoding a suicide gene. In other embodiments, the vector is a non-viral vector. In other embodiments, the non-viral vector includes, for example, a liposome, a cationic polymer vector, a lipid nanoparticle vector (LNP) or a multifunctional envelope nanocarrier.
[0274] Another aspect of the present invention provides a host cell, wherein the host cell comprises the nucleic acid molecule described in the present disclosure or the vector described in the present invention.
[0275] Another aspect of the present invention provides a protein conjugate, wherein the protein conjugate comprises the mutant described in the present invention.
[0276] Another aspect of the present invention provides a pharmaceutical composition comprising the mutant described herein, the isolated nucleic acid molecule described herein, the vector described herein, the host cell described herein, or the protein conjugate described herein, and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier can be any pharmaceutically acceptable additive, such as physiological saline, cell culture medium, glucose, water for injection, glycerol, amino acids, and combinations thereof, stabilizers, surfactants, preservatives, isotonic agents, and the like. In some embodiments, the pharmaceutical composition can be an immunogenic composition. In some embodiments, the pharmaceutical composition is a vaccine. The vaccine comprises the mutant described herein, the isolated nucleic acid molecule described herein, the vector described herein, the host cell described herein, or the protein conjugate described herein. The vaccine is a preventive or therapeutic vaccine. In some embodiments, the pharmaceutical composition can comprise one or more different mutants, isolated nucleic acid molecules, vectors, host cells, or protein conjugates described herein, such as two or three. In some embodiments, the vaccine is a protein vaccine, a nucleic acid vaccine, or a vector vaccine.
[0277] For protein vaccines, in some embodiments, the vaccine may further comprise an immunomodulator, such as an adjuvant. Any suitable adjuvant may be selected, for example, aluminum hydroxide, aluminum phosphate, MF59, or CpG. In some embodiments, the immunomodulator also comprises an immunopotentiator, for example, a cytokine, a chemokine PAMP, a TLR ligand, an immunostimulatory sequence, CpG-containing DNA, dsRNA, a ligand for a receptor that recognizes an endocytic mode, LPS, Quillaja saponin, or tucaresol.
[0278] Another aspect of the present invention is to provide the use of the mutant described in the present invention, the isolated nucleic acid molecule described in the present invention, the vector described in the present invention, the host cell described in the present invention, the protein conjugate described in the present invention or the pharmaceutical composition described in the present invention in the preparation of a product for preventing or treating RSV infection.
[0279] In some embodiments, a method for producing an immune response to RSV in a subject is also provided. The method comprises administering to the subject an effective dose of a mutant described in the present invention, an isolated nucleic acid molecule described in the present invention, a vector described in the present invention, a host cell described in the present invention, a protein conjugate described in the present invention, or a pharmaceutical composition described in the present invention. In some embodiments, the immune response can produce one or more neutralizing antibodies in the subject. In some embodiments, the immune response can trigger cellular immunity in the subject. In some embodiments, the immune response is to reduce or suppress the replication of RSV in the subject. In some embodiments, the administration can be one or more administrations. In some embodiments, the method of administration can be intramuscular injection, intraperitoneal injection, subcutaneous injection, mucosal immunization, etc.
[0280] The mutants, isolated nucleic acid molecules, vectors, host cells, protein conjugates or pharmaceutical compositions of the present invention can be administered simultaneously or in combination with other drugs including immunogenic compositions.
[0281] Another aspect of the present invention provides the use of the mutant described in the present invention, the isolated nucleic acid molecule described in the present invention, the vector described in the present invention, the host cell described in the present invention, or the protein conjugate described in the present invention in the preparation of antibodies against the prefusion conformation of RSV F protein.
[0282] Another aspect of the present invention provides the use of the mutants, isolated nucleic acid molecules, vectors, host cells, or protein conjugates described herein for detecting the presence of RSV antibodies in a sample. For example, RSV infection in a subject can be diagnosed by detecting the presence of RSV antibodies in a sample derived from the subject.
[0283] Another aspect of the present invention provides a method for preventing or treating RSV infection, comprising administering an effective dose of the pharmaceutical composition of the present invention to a patient.
[0284] Beneficial effects of the present disclosure:
[0285] In the embodiment of the present invention, based on the structural analysis of the RSV F protein before and after fusion conformation, other conformational change regions coupled with the F protein RR1 from pre-fusion to post-fusion conformational change are obtained. By introducing stabilizing mutations, the occurrence of conformational motion is prevented, and / or mutations are directly introduced in the interaction region involved in RR1 to prevent its conformational transition, and the F protein is stabilized to the pre-fusion conformational trimer state. In addition, stabilizing mutations are introduced in the tail domain of the F protein to further enhance the stability of the RSV F protein pre-fusion conformational trimer structure. Binding experiments with the pre-fusion conformational trimer-specific monoclonal antibody AM14 show that the mutants provided in the embodiment of the present invention can have strong binding activity with the AM14 monoclonal antibody, while the wild-type RSV F protein before the artificial mutation has no binding activity with the AM14 monoclonal antibody. Palivizumab binding experiments show that the mutants provided in the embodiment of the present invention and the wild-type RSV F protein before the artificial mutation all have strong binding activity with palivizumab. The above experimental results show that the introduced mutations successfully stabilize the RSV F protein in the pre-fusion conformational trimer state and fold well.
[0286] In the disclosed embodiments, an accelerated stability test was also conducted on the expressed F protein mutants. The results showed that after being placed at 37°C for 4 weeks, there was no significant change in the binding activity of the AM14 monoclonal antibody, indicating that the trimer conformation of the mutant protein before fusion remained stable.
[0287] Animal immunization experiments were also conducted in the embodiments of the present disclosure, and the experimental results showed that compared with the wild-type RSV F protein before artificial mutation, the mutants provided by the present disclosure can induce the production of higher titers of neutralizing antibodies. BRIEF DESCRIPTION OF THE DRAWINGS
[0288] Figure 1A is a diagram of the RSV F protein prefusion conformational trimer structure, and Figure 1B is a diagram of the RSV F protein postfusion conformational trimer structure, wherein the head domain and tail domain defined for vivid description of the present invention are indicated in the figure, and during the F protein transition from the prefusion conformation to the postfusion conformational process, the RR1 district (located in the head domain) and the RR2 district (located in the C-terminus and tail domain of the head domain) in which significant conformational changes occur are indicated in the figure, and Figures 1A and 1B are drawn based on the coordinate files with PDB codes 4jhw and 3rrr, respectively;
[0289] Figure 2 is a structural overlay of the pre-fusion conformation (light color) and post-fusion conformation (dark color) of the RSV F protein monomer. During the transition from the pre-fusion conformation to the post-fusion conformation of the F protein, the head domain RR1 undergoes a substantial conformational change, while α1 and α5 also undergo corresponding significant conformational motions. The enlarged image on the right shows the conformational changes of α1 and α5 before and after fusion. The pre-fusion and post-fusion conformations of the F protein monomer are drawn according to the coordinate files with PDB codes 4jhw and 3rrr, respectively.
[0290] FIG3 is an SDS-PAGE electrophoresis diagram of exemplary mutants FHM-24 and FHM-25 with mutations introduced into the head domain according to an embodiment of the present disclosure;
[0291] FIG4 is a graph showing the results of an AM14 monoclonal antibody binding experiment on exemplary mutants FHM-24 and FHM-25 with introduced mutations in the head domain, as well as wild-type RSV F protein 1 before artificial mutation and wild-type RSV F protein 2 before artificial mutation in the embodiments of the present disclosure;
[0292] FIG5 is a graph showing the results of a Palivizumab binding experiment on exemplary mutants FHM-24 and FHM-25 with introduced mutations in the head domain, as well as wild-type RSV F protein 1 before artificial mutation and wild-type RSV F protein 2 before artificial mutation in the embodiments of the present disclosure;
[0293] FIG6 is an SDS-PAGE electrophoresis diagram of the purified FHCS-1, FHCS-2, FHCS-3, FHCS-4, FHCS-5, FHCM-1, FHCM-2, FHCM-3 and FHCM-4 mutant proteins constructed in the embodiments of the present disclosure;
[0294] FIG7A is a comparison diagram of the AM14 monoclonal antibody binding experimental results of the FHCS-1, FHCS-2, FHCS-3, FHCS-4, FHCS-5, FHCM-1 and FHCM-2 mutants constructed in the disclosed embodiments and the FHM-24 mutant, as well as the wild-type RSV F protein 1 before artificial mutation and the wild-type RSV F protein 2 before artificial mutation; FIG7B is a comparison diagram of the AM14 monoclonal antibody binding experimental results of the FHCM-3 and FHCM-4 mutants constructed in the disclosed embodiments and the FHM-25 mutant, as well as the wild-type RSV F protein 1 before artificial mutation and the wild-type RSV F protein 2 before artificial mutation;
[0295] 8A is a comparison diagram of the results of a palivizumab binding experiment of the FHCS-1, FHCS-2, FHCS-3, FHCS-4, FHCS-5, FHCM-1 and FHCM-2 mutants constructed in the disclosed embodiments and the FHM-24 mutant, as well as the wild-type RSV F protein 1 before artificial mutation and the wild-type RSV F protein 2 before artificial mutation; FIG8B is a comparison diagram of the results of a palivizumab binding experiment of the FHCM-3 and FHCM-4 mutants constructed in the disclosed embodiments and the FHM-25 mutant, as well as the wild-type RSV F protein 1 before artificial mutation and the wild-type RSV F protein 2 before artificial mutation;
[0296] Figure 9 is a comparison of the RSVA2 live virus neutralizing antibody detection results of the FHCS-1, FHCS-2, FHCS-3 and FHCS-4 mutants constructed in the embodiments of the present disclosure, the FHM-24 mutant, and the wild-type RSV F protein 2 before artificial mutation.
[0297] Sequence Listing
[0298] The exemplary sequences provided by the present disclosure are shown in Tables 1-3.
[0299] Table 1. Wild-type RSV F protein amino acid sequence
[0300] Table 2. Amino acid sequence of wild-type RSV F protein before artificial mutation
[0301] Table 3 Amino acid sequences of exemplary wild-type RSV F protein mutants (after artificial mutation) DETAILED DESCRIPTION
[0302] The present disclosure discloses mutants of the RSV F protein. Those skilled in the art can refer to the contents of this disclosure and appropriately improve the process parameters to achieve the same. It should be noted that all similar substitutions and modifications are obvious to those skilled in the art and are considered to be included in this disclosure. It is obvious that relevant persons can modify or appropriately change and combine the contents described herein without departing from the content, spirit and scope of this disclosure to implement and apply the disclosed technology.
[0303] In this disclosure, unless otherwise specified, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Definitions of common terms in molecular biology can be found in Lewin's GENES XII, Jocelyn E. Krebs / Elliott S. Goldstein / Stephen T. Kilpatrick, published by Jones & Bartlett, 2018.
[0304] Unless otherwise expressly indicated, throughout the specification and claims, the term "comprise" or variations thereof such as "comprises" or "comprising" and the like will be understood to include the elements or components stated without excluding other elements or other components. The terms "a," "an," and "the" include plural referents. The term "plurality" refers to two or more. The terms "such as," "for example," and the like are intended to refer to exemplary embodiments and are not intended to limit the scope of the present disclosure.
[0305] In order to enable those skilled in the art to better understand the technical solutions of the present disclosure, the present disclosure is further described in detail below in conjunction with specific embodiments.
[0306] I. Definition
[0307] The term "wild type", also referred to as "native" or "natural", refers to a protein without the addition of non-natural mutations. In some embodiments, exemplary examples of wild type RSV F proteins are shown in SEQ ID Nos. 1-6.
[0308] The term "mutation" refers to a change in a sequence (e.g., a nucleotide or amino acid sequence) relative to the corresponding sequence in its native, wild-type, standard, or reference form (i.e., the non-mutated sequence). Amino acid mutations generally include substitutions, deletions, or insertions of amino acid residues. Mutations can be artificial or naturally occurring.
[0309] The terms "peptide," "polypeptide," and "protein" are used interchangeably and generally refer to peptides and proteins of amino acids covalently linked by peptide bonds. The term "protein" encompasses purified natural products, or products that can be produced in part or in whole using recombinant or synthetic techniques. The terms "peptide" and "protein" can refer to aggregates of proteins, such as dimers or other multimers, fusion proteins, protein variants, or derivatives thereof. The term also includes modifications of proteins, for example, proteins modified by glycosylation, acetylation, phosphorylation, pegylation, ubiquitination, and the like. Proteins may include amino acids that are not encoded by nucleic acid codons. Proteins may have amino acid sequences that are long enough to produce higher levels of tertiary and / or quaternary structure.
[0310] The term "protease cleavage site" refers to a specific amino acid motif within the amino acids of a protein or fusion protein. Within the amino acid sequence of a protein or fusion protein, it is cleaved by a specific protease that recognizes the amino acid motif. In some embodiments, examples of specific proteases include furin, trypsin, factor Xa, thrombin, or cathepsin L, etc.
[0311] The term "F0 precursor protein" refers to the RSV F protein, which is initially translated in vivo into a single-chain, inactive precursor protein, F0, consisting of 574 amino acids. The signal peptide, consisting of amino acids 1 to 25 at the N-terminus of the F0 protein, is removed by signal peptidase. Furthermore, F0 contains two furin cleavage sites at amino acids 109 / 110 and 136 / 137. Enzymatic cleavage by proteases removes the peptide at amino acids 110 to 136 (referred to as p27), generating F1, consisting of amino acids 137 to 574, and F2, consisting of amino acids 26 to 109.
[0312] The terms "head domain" and "tail domain" are defined in the present invention to vividly describe the structure of the RSV F protein. We define amino acids 1 to 485 as the head domain, and amino acids 486 to the C-terminus of the F protein as the tail domain. The approximate spatial positions of the head domain and tail domain are shown in Figure 1A.
[0313] The term "virus-like particles (VLPs)" or "pseudoviruses" refers to multiprotein structures composed of the structural proteins of a native virus but lacking all or part of the viral genome, particularly the replicative and infectious components of the viral genome, and therefore lacking the ability to replicate or infect. These multiprotein structures closely mimic their native counterparts in morphology and size and can form spontaneously following recombinant expression of viral structural proteins.
[0314] The term "protein delivery vector" refers to a protein that can serve as a carrier of an epitope peptide, that is, it can insert an epitope peptide at a specific position (e.g., inside the protein, at the N-terminus or C-terminus) so that the epitope peptide can be presented, thereby enabling the epitope peptide to be recognized by antibodies or the immune system.
[0315] The term "immunogenicity" refers to the ability of a substance to elicit, trigger, stimulate or induce an immune response in an animal to a specific antigen, with or without an adjuvant.
[0316] The term "conjugate" generally refers to any substance formed by joining two or more separate parts together. For example, a conjugate may comprise a substance formed by joining one polypeptide to one or more other polypeptides. When one part of the conjugate is a protein, the conjugate is a protein conjugate.
[0317] II. Mutation design of the RSV F protein head domain to stabilize the F protein in the prefusion conformational trimer state
[0318] Existing literature reports that most of the highly active neutralizing antibodies against RSV F protein discovered so far target the prefusion conformation (Ref: Battles MB, McLellan JSNat. Rev. Microbiol., 2019, 17: 233-245; Gilman MSA et al. PLoS Pathog., 2015, 11: e1005035; Harshbarger W., et al. MAbs, 2021, 13: 1955812.), and the neutralizing antibody titer induced by the F protein trimer in the prefusion conformation is much higher than that induced by the postfusion conformation trimer (Ref: Battles MB, McLellan JSNat. Rev. Microbiol., 2019, 17: 233-245; Krarup A. et al. (e.g., et al. Nat. Commun., 2015, 6:8143). Therefore, the F protein trimer in the prefusion conformation is the preferred antigen for the development of recombinant subunit vaccines. However, the prefusion conformation of the F protein trimer is a metastable state and can easily transition from the prefusion conformation (as shown in Figure 1A) to the postfusion conformation (as shown in Figure 1B). Stabilizing the F protein to the prefusion conformation trimer state through modification of key sites is one of the key challenges that need to be addressed in the development of recombinant subunit vaccines.
[0319] The spatial structure of the RSV F protein trimer before and after fusion has been determined by X-ray crystallography (Ref: McLellan JS, et al. Science, 2013, 340: 1113-1117. McLellan JS, et al. J. Virol., 2011, 85: 7788-7796.) and submitted to the Protein Data Bank (PDB). The spatial coordinates of the trimer before and after fusion can be downloaded from the PDB database using PDB codes 4jhw and 3rrr. Using commonly used protein structure alignment software, such as Pymol and Chimera, the pre- and post-fusion conformations were superimposed, as shown in Figure 2. The structural alignment results in Figure 2 show that from the prefusion to the postfusion conformation, the RR1 region of the head domain, as well as the RR2 region located at the C-terminus of the head domain and the tail domain, undergo significant conformational changes. Simultaneously, α1 and α5 of the head domain also undergo significant conformational motions. Therefore, the conformational changes of α1 and α5 are coupled to those of RR1. Based on this structural analysis, introducing stabilizing mutations in the α1 or α5 regions to prevent the conformational changes of α1 and α5 can, through coupled regulatory effects, prevent the conformational changes of RR1 and stabilize the F protein in the prefusion conformation. Alternatively, stabilizing mutations can be introduced directly in the interaction regions involved in RR1 to prevent the transition from the prefusion to the postfusion conformation. To this end, the present disclosure introduces mutations in the α1 helix (amino acids 73-96) or the α5 helix (amino acids 216-240) or directly in the interaction region involved in RR1, or introduces any combination of these mutations to stabilize the conformation of α1, α5, or RR1 by enhancing the interactions between the residues, thereby stabilizing the F protein in the pre-fusion conformational trimer state. Some exemplary single-site mutation designs are shown in Table 4. These single-site mutations can be combined in any way and can have similar or stronger stabilizing effects. Some exemplary mutation combinations are shown in Table 5.
[0320] Table 4 Example single-site mutation designs of RSV F protein head domain
[0321] Table 5 Example site mutation combination designs of RSV F protein head domain
[0322] III. Examples
[0323] Example 1 Plasmid construction, recombinant expression and effect verification of mutants designed by introducing artificial mutations into the head domain (Table 4 and Table 5)
[0324] The native RSV F protein is a homotrimer. To facilitate secretory expression of the protein, this example removed amino acids 514 to 574, including the transmembrane and intracellular regions, from the full-length F0 sequence. This region plays an important role in the formation of the F protein trimer. To enable the truncated sequence to assemble into trimers, the C-terminus of the truncated sequence was connected to an exogenous trimerization domain (in this example, the T4 Foldon trimerization motif) via a short linker (the sequence SAIG). Studies have shown that removing the p27 portion of the F0 sequence facilitates trimer formation (Krarup A. et al. Nat. Commun., 2015, 6:8143). In this example, the sequence 107 to 138 (RARRELPRFMNYTLNNAKKTNVTLSKKRKRRF), which contains the p27 and furin cleavage sites, was replaced with the linker QARGSGSGRS sequence. In addition, the present invention replaces the signal peptide "MELLILKANAITTILTAVTFCFASG" consisting of amino acids 1 to 25 at the N-terminus with the signal peptide sequence "MDMRVPAQLLGLLLLWLRGARC," which is suitable for the recombinant expression system HEK293, to promote secretory expression of the recombinant protein. Based on this, corresponding RSV F protein mutants were constructed according to the head domain site mutations designed in Tables 4 and 5. The amino acid sequences of the constructed mutants (excluding the signal peptide, T4 foldon, and linker) are shown in SEQ ID Nos. 35-157.
[0325] According to the amino acid sequence of SEQ ID No.35-157, a signal peptide, T4 foldon trimerization motif, connector, and an external tag sequence that facilitates purification are added to the recombinant expression system HEK293, and codon optimization is performed according to the codon preference of HEK293 to form the corresponding coding gene sequence. The coding gene sequence is constructed by whole gene synthesis or point mutation, and the Kozak sequence "GCCACC" is added to the front of the sequence and then connected to the recombinant expression vector pcDNA3.1 to form a recombinant expression plasmid. TMThe constructed pre-fusion RSV F protein mutants were recombinantly expressed using a transient expression system (Thermo Fisher), and the cell secretion supernatant was harvested 5 days after transfection. As a control, based on the above method, we also recombinantly expressed the wild-type RSV F protein before artificial mutation according to SEQ ID No. 12 (referred to as "wild-type RSV F protein 1 before artificial mutation"). In addition, we also purchased the RSV A2 strain F protein (Catalog Number: 11049-V08B) from Sino Biological as another control (referred to as "wild-type RSV F protein 2 before artificial mutation"), and its amino acid sequence is shown in SEQ ID No. 15.
[0326] To verify whether the introduction of the above mutations can stabilize the RSV F protein to the prefusion conformational trimer state, this example uses the prefusion conformational trimer to specifically bind to the monoclonal antibody AM14. The binding activity of the constructed mutants to the AM14 antibody was detected by ELISA, and compared with the AM14 monoclonal antibody binding activity of the wild-type RSV F protein 1 before artificial mutation and the wild-type RSV F protein 2 before artificial mutation. Published literature shows that the AM14 antibody binds to the epitope region at the interface between two adjacent monomers in the pre-fusion conformation of the F protein trimer (Ref: Gilman MSA et al. PLoS Pathog., 2015, 11: e1005035; Harshbarger W., et al. MAbs, 2021, 13: 1955812.). When the F protein trimer changes from the pre-fusion conformation to the post-fusion conformation, the epitope is destroyed. Therefore, the AM14 antibody cannot bind to the post-fusion conformation of the F protein. This antibody is often used for the specific recognition and detection of the pre-fusion conformation trimer structure of the F protein (Ref: Gilman MSA et al. PLoS Pathog., 2015, 11: e1005035; Harshbarger W., et al. MAbs, 2021, 13: 1955812.). al. MAbs, 2021, 13: 1955812.), and there are reports that the binding activity of AM14 monoclonal antibody is positively correlated with the neutralizing antibody titer produced by immunized animals (Ref: Che Y. et al. Sci. Transl. Med., 2023, 15: eade6422.). At the same time, to verify whether the constructed mutant can be expressed, this example uses a His tag antibody to detect its expression.
[0327] The ELISA detection process of transfection supernatant is as follows:
[0328] (1) Detection of AM14 monoclonal antibody binding activity
[0329] AM14 monoclonal antibody (Costan Bio) was diluted to 1 μg / ml using coating solution (Na2CO3-NaHCO3 solution, pH 9.6) and then coated on a 96-well enzyme-labeled plate at 100 μl / well and coated at 4°C for 8-12 h; after washing the plate with PBST solution, blocking solution (20% calf serum, 0.2% yeast extract, dissolved in PBST) was added at 100 μl / well and blocked at 37°C for 2 h; after washing the plate with PBST solution, 10-fold diluted cell secretion supernatant after centrifugation of the recombinant expression mutant (containing wild-type RSV F protein 1 before artificial mutation) and 2 μg / ml wild-type RSV F protein 2 before artificial mutation were added at 100 μl / well and incubated at 37°C for 1 h; after washing the plate with PBST solution, diluted horseradish peroxidase-labeled RSV was added. F protein rabbit monoclonal antibody (1:1000, Sino Biological) was added at 100 μl / well and incubated at 37°C for 1 h. After washing with PBST solution, color development solutions A and B were added successively, and the color was developed at room temperature for 5 min. Stop solution C was added to terminate the color development reaction. The optical density (OD) values were read at wavelengths of 450 nm and 630 nm.
[0330] (2) Detection of His tag antibody binding activity
[0331] The supernatant of the cell secretion after centrifugation of the recombinant mutant (containing the wild-type RSV F protein 1 before artificial mutation) was diluted 10 times using the coating solution and coated on a 96-well ELISA plate. F protein 2 was used as a control well, 100 μl / well, and coated at 4°C for 8-12 h; after washing with PBST solution, blocking solution was added at 100 μl / well and blocked at 37°C for 2 h; after washing with PBST solution, diluted His-tag antibody (1:2000 dilution, Sino Biological) was added at 100 μl / well and incubated at 37°C for 1 h; after washing with PBST solution, diluted horseradish peroxidase-labeled goat anti-mouse secondary antibody (1:10000, Zhongshan Jinqiao) was added at 100 μl / well and incubated at 37°C for 1 h; after washing with PBST solution, color development solutions A and B were added successively, and color was developed at room temperature for 5 min. Stop solution C was added to terminate the color development reaction; OD values were read at wavelengths of 450 nm and 630 nm.
[0332] The ELISA test results are shown in Tables 6, 7, and 8. The results show that the His tag antibody detection of most mutants has a high OD value, indicating that most of the constructed mutants can be effectively expressed. Table 6 shows that the wild-type RSV F protein 1 before artificial mutation and the wild-type RSV F protein 2 before artificial mutation have no AM14 monoclonal antibody binding activity, while Tables 7 and 8 show that a variety of head domain single-site mutants and a variety of head domain multi-site combination mutants can bind to AM14 monoclonal antibody, including FHS-1, FHS-4, FHS-5, FHS-6, FHS-11, FHS-12, FHS-14, FHS-26, FHS-45, FHS-46, FHS-47, FHS-48, FHS-49, FHS-50, FHS-65 , FHS-66, FHS-67, FHS-68, FHS-69, FHS-76, FHS-78, FHS-84, FHS-87, FHS-88, FHM-1, FHM-2, FHM-5, FHM-9, FHM-12, FHM-13, FHM-15, FHM-16, FHM-18, FHM-19, FHM-20, FHM-22, FHM-23, FHM-24, and FHM-25 mutants. The OD values of these single-site mutants or multi-site combination mutants detected by AM14 monoclonal antibody were significantly higher than those of wild-type RSV F protein 1 and wild-type RSV F protein 2 before artificial mutation, indicating that the introduction of the above mutations successfully stabilized the RSV F protein to the pre-fusion conformational trimer state.
[0333] Table 6 Binding activity of wild-type RSV F protein 1 before artificial mutation and wild-type RSV F protein 2 before artificial mutation with AM14 monoclonal antibody and His tag antibody
[0334] Table 7 Binding activity of exemplary mutants with single-site mutations introduced into the head domain of RSV F protein to AM14 monoclonal antibody and His-tag antibody
[0335] Table 8 Binding activity of exemplary mutants with multiple combined mutations introduced into the RSV F protein head domain to AM14 monoclonal antibody and His tag antibody
[0336] Example 2 Purification, Identification and Biological Activity Evaluation of Exemplary Mutants FHM-24 and FHM-25 Expressed in Example 1 with Mutations Introduced into the Head Domain
[0337] The RSV F protein head domain was introduced into the exemplary mutants FHM-24 and FHM-25 (corresponding amino acid sequences SEQ ID No. 156 and SEQ ID No. 157) and recombinant expression plasmids were cloned and expressed by Expi293. TM Transient expression was performed using an expression system (Thermo Fisher), and secretory supernatants were harvested five days after transfection. The transfection supernatant was purified by affinity chromatography using a nickel column (HisTrap FF crude prepacked column). The column was equilibrated with 20mM phosphate-150mM sodium chloride, pH 7.4, and the target protein was collected after elution with 20% and 50% elution buffer (20mM phosphate-150mM sodium chloride-500mM imidazole, pH 7.4). The purified protein was analyzed by 12% SDS-PAGE. The results, shown in Figure 3, show that the target protein monomer band corresponds to a molecular weight of approximately 50-70 kD, which is consistent with the theoretical value, indicating that the FHM-24 and FHM-25 mutants are correctly expressed.
[0338] After obtaining the purified samples of FHM-24 and FHM-25 mutants, the binding activity of the above two mutants with AM14 monoclonal antibody was detected by antibody binding experiment using the pre-fusion conformation trimer-specific monoclonal antibody AM14 to verify whether it was successfully stabilized to the pre-fusion conformation trimer state. At the same time, palivizumab was used to further verify the folding of FHM-24 and FHM-25 mutants. Palivizumab can specifically bind to the II epitope of RSV F protein. Both the pre-fusion and post-fusion F proteins contain the same conformation II epitope. Therefore, palivizumab can bind to both the pre-fusion conformation F protein and the post-fusion conformation F protein. In this experiment, wild-type RSV F protein 1 before artificial mutation and wild-type RSV F protein 2 before artificial mutation were used as controls. The specific experimental operation process is as follows: the purified FHM-24 and FHM-25 mutants and the wild-type RSV F protein 1 before artificial mutation and the wild-type RSV F protein before artificial mutation were used as controls. F protein 2 was serially diluted 2-fold using coating solution starting from 80 μg / ml (corresponding primary antibody was AM14 monoclonal antibody) and 10 μg / ml (corresponding primary antibody was palivizumab), and 100 μl / well was coated on an ELISA plate. Three replicates were made for each dilution and coated at 4°C for 8-12 h. A blank well was used as a negative control. The plate was washed with PBST solution and then blocked with blocking solution at 37°C for 2 h. After washing with PBST solution, diluted AM14 monoclonal antibody (0.1 μg / ml) or palivizumab (2 ug / ml) was added at 100 μl / well and incubated at 37°C for 1 h. After washing with PBST solution, diluted horseradish peroxidase-labeled goat anti-human secondary antibody (1:10000) was added at 100 μl / well and incubated at 37°C for 1 h. After washing the plate with the solution, add colorimetric solution A and B successively, develop the color at room temperature for 5 minutes, and then add stop solution C to terminate the colorimetric reaction; read the OD value at 450nm and 630nm wavelength, and compare the OD value of the duplicate wells with different concentrations. 450 / 630nm The mean of the values was taken and the standard deviation was calculated. The protein concentration was used as the horizontal axis and the OD values corresponding to each concentration were calculated. 450 / 630nm The mean is the vertical axis, and the line graph is drawn using Origin software.
[0339] Antibody binding experiment results are shown in Figures 4 and 5. AM14 monoclonal antibody binding experiment results (Figure 4) show that the wild-type RSV F protein 1 before the artificial mutation and the wild-type RSV F protein 2 before the artificial mutation do not have AM14 monoclonal antibody binding activity, while the exemplary mutants FHM-24 and FHM-25 that introduce mutations in the head domain present AM14 monoclonal antibody binding activity. Show that by introducing stability mutations in the head domain, RSV F protein can be stabilized in the pre-fusion conformation trimeric state, preventing the occurrence of its conformational transition from pre-fusion to post-fusion. Palivizumab binding experiment results (Figure 5) show that FHM-24 mutant, FHM-25 mutant, the wild-type RSV F protein 1 before the artificial mutation and the wild-type RSV F protein 2 before the artificial mutation all have Palivizumab binding activity. Show that these four proteins can all be correctly folded.
[0340] Example 3 Based on the introduction of mutations in the head domain of RSV F protein, the mutation design of the tail domain is added to further enhance the stability of the RSV F protein pre-fusion conformation trimer, thereby further improving its immunogenicity
[0341] The stability of the trimer structure of the RSV F protein before fusion has an important influence on its immunogenicity as an antigen. Based on the mutations in the head domain introduced in the above examples, this example also introduces mutations in the tail domain of the F protein to enhance the stability of the trimer structure of the F protein by enhancing the interaction between the three helical bundles in the RR2 region, thereby enhancing the binding activity of the AM14 monoclonal antibody and further improving its immunogenicity. Existing literature reports that the binding activity of the AM14 monoclonal antibody is positively correlated with the neutralizing antibody titer produced by immunized animals (Ref: Che Y. et al. Sci. Transl. Med., 2023, 15: eade6422.). To this end, this example introduces a single-site mutation or a combination of multiple site mutations in the RR2 region of the RSV F protein tail domain to further enhance the stability of the trimer structure of the F protein before fusion by enhancing the interaction between the three helical bundles in the RR2 region. This embodiment takes the mutants FHM-24 (head domain introduces 227N→M and 230L→F mutations) and FHM-25 (head domain introduces 227N→M, 230L→F mutations, 190S→V mutations and 193L→M mutations) introduced into the head domain as examples, and further enhances the stability of the RSV F protein trimer by introducing stability mutations into the tail domain. Some exemplary single-site mutation designs of the tail domain are shown in Table 9. These single-site mutations of the tail domain can be combined arbitrarily and can have similar or stronger stabilizing effects. Some exemplary mutation combinations are shown in Tables 10 and 11.
[0342] Table 9: Exemplary single-site mutation designs introduced into the tail domain based on the FHM-24 mutant to further enhance the stability of the RSV F protein prefusion conformation trimer
[0343] Table 10: Example site mutation combinations introduced into the tail domain based on the FHM-24 mutant to further enhance the stability of the RSV F protein prefusion conformation trimer
[0344] Table 11: Example site mutation combinations introduced into the tail domain based on the FHM-25 mutant to further enhance the stability of the RSV F protein prefusion conformation trimer
[0345] Example 4 Plasmid construction, recombinant expression, purification and biological activity verification of the mutant designed in Example 3
[0346] In order to verify whether the mutations introduced into the tail domain can further enhance the stability of the RSV F protein prefusion conformation trimer, this example uses the F protein prefusion conformation trimer-specific binding monoclonal antibody AM14 to detect the antibody binding activity of the mutant designed in Example 3, and compares it with the AM14 antibody binding activity of the FHM-24 or FHM-25 mutants before the introduction of the tail domain mutation, the wild-type RSV F protein 1 before artificial mutation, and the wild-type RSV F protein 2 before artificial mutation to evaluate the enhancing effect of the mutations introduced into the tail domain on the stability of the RSV F protein prefusion conformation trimer.
[0347] First, the amino acid sequences corresponding to the RSV F protein mutants designed in Example 3 are SEQ ID No. 158-166. Based on the corresponding amino acid sequences, a signal peptide, a T4 foldon trimerization motif, a connector, and an external tag sequence that facilitates purification were added to the recombinant expression system HEK293. Codon optimization was performed according to the codon preference of HEK293 to form the corresponding coding gene sequence. The plasmid construction and recombinant expression operation process described in Example 1 was used to construct a recombinant expression plasmid, and Expi293 was used to generate the recombinant expression plasmid. TM The mutants were recombinantly expressed using a transient expression system, and the cell secretion supernatant was harvested 5 days after transfection.
[0348] Furthermore, all mutants designed in Example 3 were purified using the purification method described in Example 1 to obtain purified mutant proteins. The purified proteins were analyzed by 12% SDS-PAGE electrophoresis, and the results are shown in Figure 6. The target protein monomer band corresponds to a molecular weight of approximately 50-70 kD, indicating that the mutants were correctly expressed.
[0349] Finally, the purified mutant samples were tested for their AM14 binding activity using the ELISA assay described in Example 2, based on the specific binding of the RSV F protein prefusion conformation trimer to the monoclonal antibody AM14. The binding activity was compared with that of the FHM-24 or FHM-25 mutants before the introduction of the tail domain mutation, the wild-type RSV F protein 1 before artificial mutation, and the wild-type RSV F protein 2 before artificial mutation, to evaluate the effect of the mutation introduced into the tail domain on the stability of the RSV F protein prefusion conformation trimer. At the same time, the folding of the constructed mutants was further verified using Palivizumab.
[0350] The results of the AM14 monoclonal antibody binding experiment are shown in Figures 7A and 7B. The results show that wild-type RSV F protein 1 before artificial mutation and wild-type RSV F protein 2 before artificial mutation have no AM14 monoclonal antibody binding activity. However, the F protein mutants after the head and tail domains have introduced mutations have significantly improved the binding activity of AM14 monoclonal antibody compared to mutants without introduced tail domain mutations (FHM-24, FHM-25) and wild-type RSV F protein 1 before artificial mutation and wild-type RSV F protein 2 before artificial mutation. The results show that the mutations introduced into the tail domain can further enhance the stability of the RSV F protein pre-fusion conformational trimer structure. The results of the Palivuzumab antibody binding experiment are shown in Figures 8A and 8B. The results show that wild-type RSV F protein 1 before artificial mutation, wild-type RSV F protein 2 before artificial mutation, F protein mutants without introduced tail domain mutations, and mutants with introduced stabilizing mutations in the tail domain all have strong Palivuzumab binding activity, indicating that these proteins can all fold correctly.
[0351] Accelerated stability study of the exemplary RSV F protein mutants constructed in Example 5
[0352] The constructed RSV F protein mutant is used as an antigen to develop a vaccine, and its stability is an important property that needs attention. In this example, the constructed exemplary RSV F protein mutants FHCS-1, FHCS-2 and FHCS-4 were subjected to heat-accelerated stability test. The mutant samples obtained after expression and purification were placed in a 37°C environment for 2 weeks and 4 weeks, respectively. At the same time, the same samples were placed in a -80°C environment for 2 weeks and 4 weeks as controls. The stability samples were diluted 2-fold starting from a concentration of 10 μg / ml (the corresponding primary antibody was AM14 monoclonal antibody) and 2.5 μg / ml (the corresponding primary antibody was palivizumab) using a coating solution. 100 μl / well was coated on an enzyme-labeled plate, and 2 replicates were made for each dilution. The binding activity of the sample to AM14 monoclonal antibody and palivizumab was then detected using the ELISA method described in Example 2.
[0353] The results of the heat-accelerated stability test are shown in Tables 12, 13, 14, and 15. The results show that after the RSV F protein mutant constructed in the present invention was placed in a 37°C environment for 4 weeks, the binding activity of the AM14 monoclonal antibody and palivizumab did not change significantly compared to the sample placed in a -80°C environment, indicating that the pre-fusion conformation trimeric structure of the constructed RSV F protein mutant remained stable after being placed in a 37°C environment for 4 weeks.
[0354] Evaluation of the Animal Immunization Effects of the Exemplary RSV F Protein Mutants Constructed in Example 6
[0355] In order to verify whether the immune effect of the RSV F protein mutants constructed by the present invention is significantly enhanced, this example conducted an animal immune effect evaluation study on the mutants FHCS-1, FHCS-2, FHCS-3, and FHCS-4, and compared the immune effects with those of the wild-type RSV F protein before artificial mutation and the mutant protein FHM-24 with only head domain mutations introduced.
[0356] The specific experimental method is: the purified exemplary F protein mutant and the wild-type RSV F protein 2 before artificial mutation are mixed with aluminum hydroxide adjuvant respectively, and then poly I-cell solution is added to prepare the vaccine. The prepared vaccine is immunized with BALB / c mice (purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd., SPF grade, female, 6-8 weeks old), 10 mice in each group. Muscle immunization is carried out at week 0 and week 2, the antigen amount is 0.5μg / mouse, the immunization volume is 0.1ml / mouse, and blood is collected 1 week after the last immunization to separate the serum. The neutralizing antibody level of the immune serum is detected by the RSV A2 live virus neutralization experiment, as follows: the serum is serially diluted 2-fold using maintenance solution (DMEM culture medium containing 2% fetal bovine serum and 1% penicillin and streptomycin), the diluted RSVA2 virus is added, and 100TCID 50 / well, and duplicate wells were made for each serum; virus control wells without serum and cell control wells without serum and virus were set at the same time, and incubated at 4 ° C for 2 h; 2 × 10 4 The number of cells in each well was added to Hep2 cell suspension and cultured in a 37°C, 5% CO2 incubator for 3 days; the neutralization results were determined by immunofluorescence method, and the serum dilution factor that was lower than the mean value of the fluorescent spots in 50% of the virus control wells was used as the neutralizing antibody titer of the serum.
[0357] As shown in Figure 9, compared to the wild-type RSV F protein before artificial mutation, the neutralizing antibody titer increased after the introduction of the head domain mutation, and the neutralizing antibody geometric mean titer (GMT) increased from 147 to 239. Further, on the basis of introducing the head domain mutation, after the tail domain mutation was introduced at the same time, the neutralizing antibody titer was further significantly improved, and the GMT increased to 588-1261, which was 4-8.58 times that of the wild-type RSV F protein before artificial mutation. The results show that the present invention stabilizes the RSV F protein to the pre-fusion conformational trimer structure state by introducing the head domain and tail domain mutations, significantly improving the immunogenicity of the protein, and providing a candidate antigen with significant technical advantages and immunoactivity advantages for the development of recombinant RSV vaccines.
[0358] The above is only a preferred embodiment of the present disclosure. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present disclosure. These improvements and modifications should also be regarded as within the scope of protection of the present disclosure.
Claims
1. A mutant of wild-type RSV F protein, wherein the mutant is an artificial mutant, characterized in that: Compared with the wild-type RSV F protein before artificial mutation, the mutant has at least one amino acid mutation site, and the amino acid mutation site includes: (a) any position between amino acids 73 to 96; or (b) any position between amino acids 216 to 240; or (c) amino acid at position 141, amino acid at position 190, amino acid at position 193, amino acid at position 195, amino acid at position 199 or amino acid at position 373.
2. The mutant according to claim 1, characterized in that Compared with the wild-type RSV F protein before artificial mutation, the mutant has multiple amino acid mutation sites, and the multiple amino acid mutation sites include: (a) at least two positions selected from any of amino acids 73 to 96; or (b) at least two positions selected from any of amino acids 216 to 240; or (c) at least one arbitrary position selected from amino acids 73 to 96, and at least one arbitrary position selected from amino acids 216 to 240.
3. The mutant according to claim 2, characterized in that Compared with the wild-type RSV F protein before artificial mutation, the mutant has multiple amino acid mutation sites, and the multiple amino acid mutation sites include any one of the following (a), (b) or (c) and a combination of (d): (a) at least two positions selected from any of amino acids 73 to 96; (b) at least two positions selected from any of amino acids 216 to 240; (c) at least one selected from any position among amino acids 73 to 96, and at least one selected from any position among amino acids 216 to 240; (d) at least one position selected from amino acid position 141, amino acid position 190, amino acid position 193, amino acid position 195, amino acid position 199 or amino acid position 373.
4. The mutant according to claim 1, 2 or 3, characterized in that: The amino acid mutation sites also include: at least one site selected from any of the 486th to 513th amino acids.
5. The mutant according to claim 1, characterized in that The wild-type RSV F protein is of subtype A or subtype B.
6. The mutant according to claim 5, characterized in that The amino acid sequence of the wild-type RSV F protein is: a sequence as shown in SEQ ID No. 1-6, or a sequence having more than 90% identity thereto and having the same or substantially the same biological function.
7. The mutant according to claim 1, characterized in that The wild-type RSV F protein before the artificial mutation is in the following form: (a) a F0 precursor protein comprising two protease cleavage sites; or (b) a F0 precursor protein that is incapable of binding a protease; or (c) a combination of an independent F1 polypeptide and an independent F2 polypeptide; or (d) a combination of F2 polypeptide-linker-F1 polypeptide; or (e) A combination of F2' polypeptide-connector-F1' polypeptide, wherein the F2' polypeptide has 1 to 10 fewer amino acid residues than the F2 polypeptide along the N-terminal direction, and the F1' polypeptide has 1 to 10 fewer amino acid residues than the F1 polypeptide along the C-terminal direction.
8. The mutant according to claim 7, characterized in that The protease is furin.
9. The mutant according to claim 7, characterized in that The amino acid sequence of the wild-type RSV F protein before artificial mutation is: a sequence as shown in SEQ ID No. 7-34, or a sequence having more than 90% identity thereto and having the same or substantially the same biological function.
10. The mutant according to claim 1, characterized in that The amino acid mutation site is selected from at least one of the 79th amino acid, the 82nd amino acid, the 92nd amino acid, the 93rd amino acid, the 96th amino acid, the 141st amino acid, the 190th amino acid, the 193rd amino acid, the 195th amino acid, the 199th amino acid, the 220th amino acid, the 224th amino acid, the 227th amino acid, the 230th amino acid, the 234th amino acid, the 238th amino acid or the 373rd amino acid.
11. The mutant according to claim 4, characterized in that The amino acid mutation site also includes: at least one selected from the 501st amino acid, the 502nd amino acid, the 505th amino acid, the 509th amino acid or the 512th amino acid.
12. The mutant according to claim 10, characterized in that The amino acid mutation sites include the following: (1) amino acid at position 92; or (2) amino acid at position 96; or (3) amino acid 227; or (4) amino acid 230; or (5) amino acid 238; or (6) amino acid 227 and amino acid 230; or (7) amino acid at position 82 and amino acid at position 227; or (8) amino acid at position 89 and amino acid at position 227; or (9) amino acid at position 92 and amino acid at position 227; or (10) amino acid at position 92 and amino acid at position 230; or (11) amino acid at position 96 and amino acid at position 227; or (12) amino acid at position 96 and amino acid at position 230; or (13) amino acid at position 96 and amino acid at position 238; or (14) amino acid at position 93 and amino acid at position 227; or (15) amino acid at position 89 and amino acid at position 230; or (16) amino acid at position 82 and amino acid at position 230; or (17) amino acid at position 93 and amino acid at position 230; or (18) amino acid 227 and amino acid 238; or (19) amino acid 230 and amino acid 238; or (20) amino acid 227 and amino acid 234; or (21) amino acid at position 82 and amino acid at position 234; or (22) amino acid 193 and amino acid 195; or (23) amino acid 190, amino acid 193 and amino acid 195; or (24) amino acid 193 and amino acid 199; or (25) amino acid 141 and amino acid 373; or (26) amino acid at position 82 and amino acid at position 224; or (27) amino acid at position 92 and amino acid at position 238; or (28) amino acid 79 and amino acid 220; or (29) amino acid 97 and amino acid 291; or (30) amino acid at position 93 and amino acid at position 234; or (31) amino acid at position 92 and amino acid at position 234; or (32) amino acid 193, amino acid 227, and amino acid 230; or (33) amino acid 190, amino acid 193 and amino acid 230; or (34) amino acid 193 and amino acid 230; or (35) amino acid 190, amino acid 193, amino acid 227, and amino acid 230; or (36) amino acid at position 93, amino acid at position 230, and amino acid at position 234; or (37) amino acid at position 93, amino acid at position 193, amino acid at position 230, and amino acid at position 234; or (38) Amino acid 93, amino acid 190, amino acid 193 and amino acid 234 Acid; or (39) amino acid at position 93, amino acid at position 227, amino acid at position 193, and amino acid at position 234; or (40) amino acid at position 93, amino acid at position 234, and amino acid at position 373; or (41) amino acid 230, amino acid 238 and amino acid 373; or (42) amino acid at position 93, amino acid at position 141, and amino acid at position 234; or (43) amino acid at position 93, amino acid at position 141, amino acid at position 230, and amino acid at position 234; or (44) amino acid 141, amino acid 230, and amino acid 238; or (45) amino acid 227, amino acid 230 and amino acid 373; or (46) amino acid at position 93, amino acid at position 227, and amino acid at position 234; or (47) amino acid at position 93, amino acid at position 227, amino acid at position 230, and amino acid at position 234; or (48) amino acid at position 93, amino acid at position 227, amino acid at position 234, and amino acid at position 373; or (49) amino acid 227, amino acid 230, amino acid 238 and amino acid 373.
13. The mutant according to claim 11, characterized in that The amino acid mutation sites also include the following: (1) amino acid 509; or (2) amino acid 505; or (3) amino acid 502; or (4) amino acid 501; or (5) amino acid 505 and amino acid 509; or (6) amino acid at position 502 and amino acid at position 509; or (7) amino acid at position 501 and amino acid at position 509; or (8) amino acid at position 502 and amino acid at position 505; or (9) amino acid at position 501 and amino acid at position 505; or (10) amino acid at position 502, amino acid at position 505, and amino acid at position 509; or (11) amino acid at position 501, amino acid at position 505 and amino acid at position 509.
14. The mutant according to claim 12, characterized in that The amino acid mutation sites include the following: (1) amino acid at position 92; or (2) amino acid at position 96; or (3) amino acid 227; or (4) amino acid 230; or (5) amino acid 238; or (6) amino acid 227 and amino acid 230; or (7) amino acid at position 92 and amino acid at position 227; or (8) amino acid at position 92 and amino acid at position 230; or (9) amino acid 227 and amino acid 238; or (10) amino acid 230 and amino acid 238; or (11) amino acid at position 93 and amino acid at position 234; or (12) amino acid at position 92 and amino acid at position 234; or (13) amino acid 193, amino acid 227 and amino acid 230; or (14) amino acid 190, amino acid 193, amino acid 227, and amino acid 230; or (15) amino acid at position 93, amino acid at position 230, and amino acid at position 234; or (16) amino acid at position 93, amino acid at position 234, and amino acid at position 373; or (17) amino acid 230, amino acid 238 and amino acid 373; or (18) amino acid at position 93, amino acid at position 141, and amino acid at position 234; or (19) amino acid at position 93, amino acid at position 141, amino acid at position 230, and amino acid at position 234; or (20) amino acid 141, amino acid 230, and amino acid 238; or (21) amino acid 227, amino acid 230, and amino acid 373; or (22) amino acid at position 93, amino acid at position 227, and amino acid at position 234; or (23) amino acid at position 93, amino acid at position 227, amino acid at position 234, and amino acid at position 373; or (24) amino acid 190, amino acid 193 and amino acid 230; or (25) amino acid 193 and amino acid 230; or (26) amino acid at position 93, amino acid at position 193, amino acid at position 230, and amino acid at position 234; or (27) amino acid at position 93, amino acid at position 190, amino acid at position 193, and amino acid at position 234; or (28) amino acid at position 93, amino acid at position 227, amino acid at position 193, and amino acid at position 234; or (29) amino acid at position 93, amino acid at position 227, amino acid at position 230, and amino acid at position 234; or (30) amino acid 227, amino acid 230, amino acid 238 and amino acid 373.
15. The mutant according to claim 13, characterized in that The amino acid mutation sites also include the following: (1) amino acid 509; or (2) amino acid 505; or (3) amino acid 505 and amino acid 509; or (4) amino acid 502 and amino acid 509; or (5) Amino acid at position 501 and amino acid at position 509.
16. The mutant according to claim 1, characterized in that The amino acid mutation site includes at least one of the following: (1) amino acid 79 is substituted by C and amino acid 220 is substituted by C; or (2) amino acid 82 is substituted by C and amino acid 224 is substituted by C; or (3) amino acid 92 is substituted by C and amino acid 234 is substituted by C; or (4) amino acid 93 is substituted by C and amino acid 234 is substituted by C; or (5) the amino acid at position 82 is substituted by L; or (6) the amino acid at position 92 is substituted by L, I, M, F, Y or W; or (7) the amino acid at position 96 is substituted by M or Y; or (8) the amino acid at position 141 is substituted by M, F, Y or W; or (9) amino acid 190 is substituted by V; or (10) the amino acid at position 193 is substituted by M, F, Y or W; or (11) the amino acid at position 195 is substituted by M, F, Y or W; or (12) the amino acid at position 199 is substituted by M, F, Y or W; or (13) the amino acid at position 227 is substituted by A, V, L, I, M, S, T or Q; or (14) amino acid 230 is substituted by F; or (15) the amino acid at position 238 is substituted by L, I, M, F, Y or W; or (16) The amino acid at position 373 is substituted by M, F or Y.
17. The mutant according to claim 4, characterized in that The amino acid mutation site also includes at least one of the following situations: (1) the amino acid at position 501 is substituted by V, L, I, M, F, W, Y, P or R; or (2) the amino acid at position 502 is substituted by V, L, I, M, F, W, Y, P or R; or (3) the amino acid at position 505 is substituted by M or W; or (4) the amino acid at position 509 is substituted by G, A, V, L, I, M, F, W, P, S, T, C, Y, Q, K, R or H; or (5) The amino acid at position 512 is substituted by I, F, M, Y, R or K.
18. The mutant according to claim 16, characterized in that The amino acid mutation sites include the following: (1) the amino acid at position 92 is substituted by I, M, F, Y or W; or (2) the amino acid at position 96 is substituted by Y; or (3) the amino acid at position 227 is substituted by M, V or I; or (4) amino acid 230 is substituted by F; or (5) the amino acid at position 238 is substituted by L, I, M or W; or (6) the amino acid at position 227 is substituted by M or V, and the amino acid at position 230 is substituted by F; or (7) the amino acid at position 82 is substituted by L and the amino acid at position 227 is substituted by M; or (8) the amino acid at position 92 is substituted by M or L, and the amino acid at position 227 is substituted by M or V; or (9) the amino acid at position 92 is substituted by M or L, and the amino acid at position 230 is substituted by F; or (10) the amino acid at position 96 is substituted by Y and the amino acid at position 227 is substituted by M or V; or (11) the amino acid at position 96 is substituted by Y and the amino acid at position 230 is substituted by F; or (12) the amino acid at position 96 is substituted by Y, and the amino acid at position 238 is substituted by L, I, M or W; or (13) amino acid at position 89 is substituted by L and amino acid at position 230 is substituted by F; or (14) the amino acid at position 227 is substituted by M and the amino acid at position 238 is substituted by L, I, M or W; or (15) the amino acid at position 230 is substituted by F, and the amino acid at position 238 is substituted by L, I, M or W; or (16) the amino acid at position 193 is substituted by M, and the amino acid at position 195 is substituted by M, F or Y; or (17) the amino acid at position 190 is substituted by V, the amino acid at position 193 is substituted by M, and the amino acid at position 195 is substituted by M, F or Y; or (18) the amino acid at position 193 is substituted by M, and the amino acid at position 199 is substituted by M or F; or (19) the amino acid at position 141 is substituted by M or F, and the amino acid at position 373 is substituted by M, F or Y; or (20) amino acid at position 82 is substituted by C and amino acid at position 224 is substituted by C; or (21) the amino acid at position 92 is substituted by C, and the amino acid at position 238 is substituted by C; or (22) amino acid 79 is substituted by C and amino acid 220 is substituted by C; or (23) amino acid 93 is substituted by C and amino acid 234 is substituted by C; or (24) amino acid at position 92 is substituted by C and amino acid at position 234 is substituted by C; or (25) amino acid position 193 is substituted by M, amino acid position 227 is substituted by M or V, and amino acid position 230 is substituted by F; or (26) the amino acid at position 190 is substituted by V, the amino acid at position 193 is substituted by M, and the amino acid at position 230 is substituted by F; or (27) amino acid 193 is substituted by M and amino acid 230 is substituted by F; or (28) the amino acid at position 190 is substituted by V, the amino acid at position 193 is substituted by M, the amino acid at position 227 is substituted by M or V, and the amino acid at position 230 is substituted by F; or (29) amino acid position 93 is substituted by C, amino acid position 230 is substituted by F, and amino acid position 234 is substituted by C; or (30) the amino acid at position 93 is substituted by C, the amino acid at position 193 is substituted by M, the amino acid at position 230 is substituted by F, and the amino acid at position 234 is substituted by C; or (31) the amino acid at position 93 is substituted by C, the amino acid at position 190 is substituted by V, the amino acid at position 193 is substituted by M, and the amino acid at position 234 is substituted by C; or (32) the amino acid at position 93 is substituted by C, the amino acid at position 227 is substituted by M or V, and the amino acid at position 234 is substituted by C; or (33) the amino acid at position 93 is substituted by C, the amino acid at position 193 is substituted by M, the amino acid at position 227 is substituted by M or V, and the amino acid at position 234 is substituted by C; or (34) amino acid position 93 is substituted by C, amino acid position 234 is substituted by C, and amino acid position 373 is substituted by M, F or Y; or (35) the amino acid at position 230 is substituted by F, the amino acid at position 238 is substituted by L, I, M or W, and the amino acid at position 373 is substituted by M, F or Y; or (36) the amino acid at position 93 is substituted by C, the amino acid at position 141 is substituted by M or F, and the amino acid at position 234 is substituted by C; or (37) The 93rd amino acid was replaced by C, the 141st amino acid was replaced by M or F, and the 230th amino acid was replaced by The amino acid at position 234 is substituted by F, and the amino acid at position 234 is substituted by C; or (38) the amino acid at position 141 is substituted by M or F, the amino acid at position 230 is substituted by F, and the amino acid at position 238 is substituted by L, I, M or W; or (39) the amino acid at position 227 is substituted by M or V, the amino acid at position 230 is substituted by F, and the amino acid at position 373 is substituted by M, F or Y; or (40) the amino acid at position 93 is substituted by C, the amino acid at position 227 is substituted by M or V, the amino acid at position 230 is substituted by F, and the amino acid at position 234 is substituted by C; or (41) the amino acid at position 93 is substituted by C, the amino acid at position 227 is substituted by M or V, the amino acid at position 234 is substituted by C, and the amino acid at position 373 is substituted by M, F or Y; or (42) The amino acid at position 227 is substituted by M or V, the amino acid at position 230 is substituted by F, the amino acid at position 238 is substituted by L, I, M or W, and the amino acid at position 373 is substituted by M, F or Y.
19. The mutant according to claim 17, characterized in that The amino acid mutation sites also include the following: (1) the amino acid at position 509 is substituted by F, M or L; or (2) the amino acid at position 505 is substituted by W; or (3) the amino acid at position 502 is substituted by Y; or (4) the amino acid at position 501 is substituted by M; or (5) the amino acid at position 505 is substituted by W and the amino acid at position 509 is substituted by F, L or M; or (6) the amino acid at position 502 is substituted by Y and the amino acid at position 509 is substituted by F; or (7) amino acid 501 is substituted by M and amino acid 509 is substituted by F; or (8) the amino acid at position 502 is substituted by Y and the amino acid at position 505 is substituted by W; or (9) the amino acid at position 501 is substituted by M and the amino acid at position 505 is substituted by W; or (10) the amino acid at position 502 is substituted by Y, the amino acid at position 505 is substituted by W, and the amino acid at position 509 is substituted by F; or (11) The amino acid at position 501 is substituted by M, the amino acid at position 505 is substituted by W, and the amino acid at position 509 is substituted by F.
20. The mutant according to claim 18, characterized in that The amino acid sequence of the mutant is: (1) the amino acid at position 92 is substituted by I, M, F, Y or W; or (2) the amino acid at position 96 is substituted by Y; or (3) the amino acid at position 227 is substituted by M or V; or (4) amino acid 230 is substituted by F; or (5) the amino acid at position 238 is substituted by L, I, M or W; or (6) the amino acid at position 227 is substituted by M or V, and the amino acid at position 230 is substituted by F; or (7) the amino acid at position 92 is substituted by M, and the amino acid at position 227 is substituted by M or V; or (8) the amino acid at position 92 is substituted by M, and the amino acid at position 230 is substituted by F; or (9) the amino acid at position 227 is substituted by M or V, and the amino acid at position 238 is substituted by L or I; or (10) the amino acid at position 230 is substituted by F, and the amino acid at position 238 is substituted by L or I; or (11) the amino acid at position 96 is substituted by Y and the amino acid at position 227 is substituted by M or V; or (12) the amino acid at position 96 is substituted by Y and the amino acid at position 230 is substituted by F; or (13) the amino acid at position 96 is substituted by Y, and the amino acid at position 238 is substituted by L, I, M or W; or (14) the amino acid at position 93 is substituted by C, and the amino acid at position 234 is substituted by C; or (15) the amino acid at position 92 is substituted by C, and the amino acid at position 234 is substituted by C; or (16) amino acid position 193 is substituted by M, amino acid position 227 is substituted by M or V, and amino acid position 230 is substituted by F; or (17) the amino acid at position 190 is substituted by V, the amino acid at position 193 is substituted by M, the amino acid at position 227 is substituted by M or V, and the amino acid at position 230 is substituted by F; or (18) amino acid position 93 is substituted by C, amino acid position 230 is substituted by F, and amino acid position 234 is substituted by C; or (19) the amino acid at position 93 is substituted by C, the amino acid at position 234 is substituted by C, and the amino acid at position 373 is substituted by M or F; or (20) the amino acid at position 230 is substituted by F, the amino acid at position 238 is substituted by L or I, and the amino acid at position 373 is substituted by M or F; or (21) the amino acid at position 93 is substituted by C, the amino acid at position 141 is substituted by M or F, and the amino acid at position 234 is substituted by C; or (22) the amino acid at position 93 is substituted by C, the amino acid at position 141 is substituted by M or F, the amino acid at position 230 is substituted by F, and the amino acid at position 234 is substituted by C; or (23) the amino acid at position 141 is substituted by M or F, the amino acid at position 230 is substituted by F, and the amino acid at position 238 is substituted by L or I; or (24) amino acid position 227 is substituted by M or V, amino acid position 230 is substituted by F, and amino acid position 373 is substituted by M or F; or (25) The amino acid at position 93 was substituted by C, the amino acid at position 227 was substituted by M or V, and the amino acid at position 234 was substituted by The amino acid at position is replaced by C; or (26) the amino acid at position 93 is substituted by C, the amino acid at position 227 is substituted by M or V, the amino acid at position 234 is substituted by C, and the amino acid at position 373 is substituted by M or F; or (27) the amino acid at position 190 is substituted by V, the amino acid at position 193 is substituted by M, and the amino acid at position 230 is substituted by F; or (28) the amino acid at position 193 is substituted by M, and the amino acid at position 230 is substituted by F; or (29) the amino acid at position 93 is substituted by C, the amino acid at position 193 is substituted by M, the amino acid at position 230 is substituted by F, and the amino acid at position 234 is substituted by C; or (30) amino acid position 93 is substituted by C, amino acid position 190 is substituted by V, amino acid position 193 is substituted by M and amino acid position 234 is substituted by C; or (31) The amino acid at position 93 is substituted by C, or the amino acid at position 227 is substituted by M or V, the amino acid at position 193 is substituted by M, and the amino acid at position 234 is substituted by C. (32) The amino acid at position 93 is substituted by C, the amino acid at position 227 is substituted by M or V, the amino acid at position 230 is substituted by F, and the amino acid at position 234 is substituted by C. (33) The amino acid at position 227 is substituted by M or V, the amino acid at position 230 is substituted by F, the amino acid at position 238 is substituted by L or I, and the amino acid at position 373 is substituted by M or F.
21. The mutant according to claim 19, characterized in that The amino acid mutation sites also include the following: (1) the amino acid at position 509 is substituted by F, M or L; or (2) the amino acid at position 505 is substituted by W; or (3) the amino acid at position 505 is substituted by W, and the amino acid at position 509 is substituted by F or L; or (4) the amino acid at position 502 is substituted by Y, and the amino acid at position 509 is substituted by F; or (5) The amino acid at position 501 is substituted by M, and the amino acid at position 509 is substituted by F.
22. The mutant according to claim 16, characterized in that The amino acid sequence of the mutant is: a sequence as shown in SEQ ID No. 35-166, or a sequence having more than 90% identity therewith and having the same or substantially the same biological function.
23. The mutant according to claim 1, characterized in that The mutant is in the form of a trimer.
24. The mutant according to claim 23, characterized in that The trimer form is a homotrimer form.
25. The mutant according to claim 1, characterized in that The C-terminus of the mutant lacks the transmembrane region and the intracellular region.
26. The mutant according to claim 1 or 25, characterized in that The C-terminus of the mutant is directly or indirectly connected to a trimerization domain.
27. The mutant according to claim 26, characterized in that The trimerization domain is GCN4 leucine zipper, collagen or T4 foldon.
28. The mutant according to claim 26, characterized in that The C-terminus of the mutant is connected to the trimerization domain via a linker.
29. The mutant according to claim 28, characterized in that The connector is a repeating sequence of GS, a repeating sequence of GGS, a repeating sequence of SAIG, a repeating sequence of GSS or a repeating sequence of GG.
30. The mutant according to claim 1, characterized in that The mutant also comprises a functional tag.
31. A virus-like particle, characterized in that The virus-like particle comprises the mutant according to any one of claims 1 to 30.
32. An isolated nucleic acid molecule, characterized in that The isolated nucleic acid molecule encodes the mutant according to any one of claims 1 to 30.
33. A carrier, characterized in that The vector comprises the sequence of the nucleic acid molecule according to claim 30 or the mutant according to any one of claims 1 to 30.
34. The carrier according to claim 33, characterized in that The vector is a protein expression vector, a gene delivery vector or a protein delivery vector.
35. The carrier according to claim 34, characterized in that The gene delivery vector is a viral vector or a non-viral vector; The viral vector includes a retroviral vector, a lentiviral vector, an adenoviral vector, an adeno-associated viral vector, a poxvirus vector, a herpes simplex virus vector or a Sendai virus vector; the non-viral vector includes a liposome, a cationic polymer vector, a lipid nanoparticle vector or a multifunctional envelope nanocarrier.
36. A host cell, characterized in that The host cell comprises the nucleic acid molecule of claim 32 or the vector of any one of claims 33 to 35.
37. A protein conjugate, characterized in that The protein conjugate comprises the mutant as described in any one of claims 1 to 30.
38. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the mutant according to any one of claims 1 to 30, the isolated nucleic acid molecule according to claim 32, the vector according to claims 33 to 35, the host cell according to claim 36, the protein conjugate according to claim 37, and a pharmaceutically acceptable carrier.
39. The pharmaceutical composition according to claim 38, characterized in that The pharmaceutical composition is a vaccine.
40. The pharmaceutical composition according to claim 39, characterized in that The vaccine is a protein vaccine, a nucleic acid vaccine or a vector vaccine.
41. Use of the mutant described in any one of claims 1 to 30, the virus-like particle described in claim 31, the isolated nucleic acid molecule described in claim 32, the vector described in claims 33 to 35, the host cell described in claim 36, the protein conjugate described in claim 37 or the pharmaceutical composition described in claims 38 to 40 in the preparation of a product for preventing or treating RSV infection.
42. Use of the mutant according to any one of claims 1 to 30, the isolated nucleic acid molecule according to claim 32, the vector according to claims 33 to 35, and the host cell according to claim 36 in the preparation of antibodies against the pre-fusion conformation of RSV F protein.
43. A method for preventing or treating RSV infection, characterized in that An effective dose of the pharmaceutical composition according to claims 38 to 40 is administered to a patient.
Citation Information
Patent Citations
Recombinant fusion protein containing bat hepatitis virus core protein, preparation method and applications thereof
CN106986942A
Recombinant fusion protein containing arctic ground squirrel hepatitis virus core protein, preparation method and applications thereof
CN106986943A
Recombinant respiratory tract syncytial virus multi-epitope chimeric vaccine, and preparation method and application thereof
CN111166881A
Stabilized soluble prefusion RSV F polypeptides
CN105188745A
Stabilized soluble pre-fusion RSV f polypeptides
CN105408348A
Cited By
Respiratory syncytial virus f protein mutant and use thereof
WO2026158514A1
